<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width,initial-scale=1" />
<title>Antibiotic & Infection Guide ‚Äî Complete</title>
<link rel="icon" href="mutant-icon.png" type="image/png">
<style>
  :root{
    --nav-w:300px;
    --header-h:64px;
    --blue:#004080;
    --muted:#f6f8fb;
    --card:#ffffff;
  }
  html{scroll-behavior:smooth}
  html,body{height:100%;margin:0;font-family:Inter,Arial,Helvetica,sans-serif;background:#fbfcfe;color:#1f2937}
  /* Layout */
  header{
    position:fixed;
    left:var(--nav-w);
    right:0;
    top:0;
    height:var(--header-h);
    background:var(--blue);
    color:#fff;
    display:flex;
    align-items:center;
    gap:12px;
    padding:0 16px;
    z-index:1200;
  }
  header img{height:44px;width:44px;object-fit:contain}
  header h1{font-size:1.05rem;margin:0;font-weight:600}
  header .search { margin-left:auto; width:420px; max-width:40vw; }
  header .search input{width:100%;padding:8px;border-radius:8px;border:0;font-size:0.95rem}

  nav#sidebar{
    position:fixed;
    top:0;
    left:0;
    width:var(--nav-w);
    height:100vh;
    background:var(--muted);
    border-right:1px solid #e2e8f0;
    padding:8px 12px;
    box-sizing:border-box;
    overflow:auto;
  }
  #sidebar .title{padding:6px 8px;font-weight:700;color:var(--blue);font-size:1rem}
  #sidebar .search-small{padding:8px}
  #sidebar input[type="text"]{width:100%;padding:8px;border-radius:8px;border:1px solid #e6eef8}

  #sidebar ul{list-style:none;padding:6px;margin:0}
  #sidebar li{margin:6px 0}
  #sidebar a{display:block;padding:8px 10px;color:#0b2545;text-decoration:none;border-radius:6px}
  #sidebar a:hover{background:#e8f1ff}

  main{
    margin-left:var(--nav-w);
    padding:calc(var(--header-h) + 18px) 22px 40px 22px;
    min-height:100vh;
    box-sizing:border-box;
  }

  section{margin-bottom:20px; scroll-margin-top: calc(var(--header-h) + 12px);}
  h2{color:var(--blue); margin:0 0 10px 0}
  .muted{color:#475569;font-size:0.95rem}
  p, li {color:#0b2338;line-height:1.4}

  /* Collapsible */
  .collapsible{
    background:#eef6ff;
    border:1px solid #d7eafc;
    color:var(--blue);
    padding:10px 12px;
    width:100%;
    text-align:left;
    cursor:pointer;
    border-radius:8px;
    font-weight:700;
    margin-top:12px;
    box-sizing:border-box;
  }
  .collapsible:after{content:'+';float:right;font-weight:700}
  .collapsible.active{background:#e3f0ff}
  .collapsible.active:after{content:'‚àí'}
  .panel{
    display:none;
    padding:12px;
    margin-top:8px;
    background:var(--card);
    border-radius:8px;
    border:1px solid #eef2f6;
  }

  table{width:100%;border-collapse:collapse;margin-top:8px}
  th,td{border:1px solid #e6edf6;padding:8px;text-align:left;font-size:14px}
  th{background:#eaf4ff;color:#023e73;font-weight:700}

  .calculator{border:1px solid #e6edf6;padding:12px;border-radius:8px;background:#fff;margin-top:10px}
  .small{font-size:0.92rem;color:#475569}
  .badge{display:inline-block;padding:4px 8px;border-radius:16px;background:#fff;border:1px solid #e6eef8;font-size:12px;margin-right:6px}

  @media (max-width:980px){
    header{left:0}
    nav#sidebar{position:relative;width:100%;height:auto;border-right:none;border-bottom:1px solid #e6edf6;padding-bottom:12px}
    main{margin-left:0;padding-top:calc(var(--header-h) + 10px)}
  }
</style>
</head>
<body>

<nav id="sidebar" aria-label="Main navigation">
  <div class="title">Antimicrobial Guide</div>

  <div class="search-small">
    <input type="text" id="sidebarSearch" placeholder="Quick search (pathogen / drug / syndrome)" />
  </div>

  <ul>
    <li><a href="#homepage">Home ‚Äî ID Approach</a></li>
    <li><a href="#empiric-therapy">Empiric Therapy</a></li>
    <li><a href="#anatomic-infections">Infections by Site</a></li>
    <li><a href="#high-yield-syndromes">High-Yield Syndromes</a></li>
    <li><a href="#sepsis">Sepsis</a></li>
    <li><a href="#pathogen-guidance">Pathogen Guidance</a></li>
    <li><a href="#pathogen-overview">Pathogen Overview</a></li>
    <li><a href="#antibiotic-classes">Antibiotic Classes</a></li>
    <li><a href="#fungal-infections">Fungal Infections</a></li>
    <li><a href="#viral-infections">Viral Infections</a></li>
    <li><a href="#tickborne-infections">Tickborne Infections</a></li>
    <li><a href="#viral-encephalopathies">Viral Encephalopathies</a></li>
    <li><a href="#calculators">Calculators</a></li>
    <li><a href="#renal-dosing">Renal Dosing</a></li>
    <li><a href="#iv-to-po">IV to PO Conversion</a></li>
    <li><a href="#duration-therapy">Duration of Therapy</a></li>
    <li><a href="#penicillin-allergy">Penicillin Allergy</a></li>
    <li><a href="#blood-culture-interpretation">Blood Culture Interpretation</a></li>
    <li><a href="#opportunistic-infections">Opportunistic Infections</a></li>
    <li><a href="#antibiogram-guide">Antibiogram Guidance</a></li>
    <li><a href="#opat">OPAT Guide</a></li>
    <li><a href="#prophylaxis">Prophylaxis Tables</a></li>
    <li><a href="#references">References</a></li>
  </ul>

  <div style="padding:12px;border-top:1px solid #e2e8f0;margin-top:12px;">
    <div style="font-weight:700;color:#004080;margin-bottom:8px;font-size:13px;">üìö Suite Navigation</div>
    <a href="index.html" style="display:block;padding:6px 10px;color:#0b2545;text-decoration:none;border-radius:6px;font-size:13px;background:#e8f1ff;margin-bottom:4px;">üè† Home</a>
    <a href="im_guide.html" style="display:block;padding:6px 10px;color:#0b2545;text-decoration:none;border-radius:6px;font-size:13px;background:#e8f1ff;margin-bottom:4px;">üìö IM Guide (148)</a>
    <a href="lab_values.html" style="display:block;padding:6px 10px;color:#0b2545;text-decoration:none;border-radius:6px;font-size:13px;background:#e8f1ff;margin-bottom:4px;">üî¨ Lab Values</a>
    <a href="dx_framework.html" style="display:block;padding:6px 10px;color:#0b2545;text-decoration:none;border-radius:6px;font-size:13px;background:#e8f1ff;margin-bottom:4px;">ü©∫ Dx Framework</a>
    <a href="drug_interactions.html" style="display:block;padding:6px 10px;color:#0b2545;text-decoration:none;border-radius:6px;font-size:13px;background:#e8f1ff;margin-bottom:4px;">üíä Drug Interactions</a>
    <a href="procedures_guide.html" style="display:block;padding:6px 10px;color:#0b2545;text-decoration:none;border-radius:6px;font-size:13px;background:#e8f1ff;margin-bottom:4px;">ü©∫ Procedures</a>
  </div>
</nav>

<header role="banner">
  <img src="mutant-icon.png" alt="logo" onerror="this.style.display='none'">
  <h1>Antibiotic & Infection Guide <span style="font-size: 0.6em; color: #ff6b6b; font-weight: 600;">BUILD #3</span></h1>
  <div class="search">
    <input id="globalSearch" type="text" placeholder="Search everything ‚Äî pathogen, drug, syndrome..." />
  </div>
</header>

<main id="main">

<!-- HOME -->
<section id="homepage" aria-labelledby="home-heading">
  <h2 id="home-heading">Home ‚Äî Basic ID Approach</h2>
  <p class="muted">Concise inpatient approach: history, source identification, empiric therapy, source control, stewardship.</p>
  <ul>
    <li>History: travel, exposures (ticks, animals), recent healthcare/antibiotics, devices.</li>
    <li>Exam: targeted to suspected source; document entry points, devices, neurologic status.</li>
    <li>Diagnostics: obtain blood cultures (2 sets), urine, wound or respiratory cultures before antibiotics when possible.</li>
    <li>Empiric therapy: cover likely pathogens given site, severity, and local antibiogram; reassess at 48‚Äì72 hrs.</li>
    <li>Source control: drain abscess, remove infected devices, debride necrotic tissue ‚Äî essential.</li>
  </ul>

  <h3>Clinical pearls</h3>
  <ul>
    <li>Sepsis: give broad-spectrum antibiotics within 1 hour of recognition; fluids and source control.</li>
    <li>Neutropenic fever: immediate anti-pseudomonal IV therapy.</li>
    <li>Always check renal function before dosing; many agents require adjustment.</li>
  </ul>
</section>

<!-- EMPIRIC THERAPY -->
<section id="empiric-therapy">
  <h2>Empiric Therapy</h2>

  <button class="collapsible">Gram-Positive Cocci (common regimens)</button>
  <div class="panel">
    <table>
      <thead><tr><th>Organism/Group</th><th>Empiric</th><th>Dose / Route</th><th>Notes / Duration</th></tr></thead>
      <tbody>
        <tr><td>MSSA</td><td>Nafcillin / Oxacillin</td><td>Nafcillin 2 g IV q4h</td><td>7‚Äì14 d; longer for endocarditis/osteomyelitis</td></tr>
        <tr><td>MRSA</td><td>Vancomycin</td><td>15 mg/kg IV q12h (AUC/CrCl adjust)</td><td>Monitor levels; 7‚Äì21 d</td></tr>
        <tr><td>Streptococci</td><td>Penicillin G / Ceftriaxone</td><td>Pen G 4 MU IV q4h; Ceftriaxone 2 g IV q24h</td><td>10‚Äì14 d (site dependent)</td></tr>
        <tr><td>Enterococcus spp.</td><td>Ampicillin ¬± Gentamicin (synergy)</td><td>Ampicillin 2 g IV q4h</td><td>UTI shorter; endocarditis 4‚Äì6 weeks</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Gram-Negative Rods (common regimens)</button>
  <div class="panel">
    <table>
      <thead><tr><th>Group</th><th>Empiric</th><th>Dose</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td>Enterobacteriaceae (E. coli, Klebsiella)</td><td>Ceftriaxone / Cefepime / Piperacillin-tazobactam</td><td>Ceftriaxone 1‚Äì2 g IV q24h; Cefepime 2 g IV q8h; Pip-tazo 4.5 g IV q6‚Äì8h</td><td>Consider carbapenem for ESBL</td></tr>
        <tr><td>Pseudomonas</td><td>Cefepime / Piperacillin-tazobactam / Meropenem</td><td>Cefepime 2 g IV q8h; Meropenem 1 g IV q8h</td><td>Consider combination therapy if critically ill</td></tr>
        <tr><td>Burkholderia</td><td>Ceftazidime ¬± TMP-SMX</td><td>Ceftazidime 2 g IV q8h</td><td>CF isolates often resistant; tailor to suscept</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Anaerobes / Mixed</button>
  <div class="panel">
    <table>
      <thead><tr><th>Group</th><th>Empiric</th><th>Dose</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td>Bacteroides / Prevotella</td><td>Pip-tazo or Carbapenem or Metronidazole combo</td><td>Metronidazole 500 mg IV q8h</td><td>Source control critical in IAIs</td></tr>
        <tr><td>Clostridioides difficile</td><td>Oral Vancomycin or Fidaxomicin</td><td>Vancomycin 125‚Äì500 mg PO q6h</td><td>Follow current guideline durations</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Intracellular / Atypical</button>
  <div class="panel">
    <table>
      <thead><tr><th>Organism</th><th>Empiric</th><th>Dose</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td>Legionella</td><td>Levofloxacin or Azithromycin</td><td>Levo 750 mg IV/PO q24h</td><td>Consider in severe CAP</td></tr>
        <tr><td>Chlamydia / Mycoplasma</td><td>Doxycycline</td><td>Doxy 100 mg PO/IV q12h</td><td>Atypical coverage for CAP</td></tr>
        <tr><td>Nocardia</td><td>TMP-SMX (high-dose)</td><td>TMP 15 mg/kg/day IV divided q6‚Äì8h</td><td>Long courses; CNS requires higher dose</td></tr>
      </tbody>
    </table>
  </div>
</section>

<!-- ANATOMIC -->
<section id="anatomic-infections">
  <h2>Infections by Anatomic Site</h2>

  <button class="collapsible">Head & Neck</button>
  <div class="panel">
    <ul>
      <li>Sinusitis (bacterial): Amoxicillin-clavulanate 875/125 mg PO BID √ó5‚Äì7 days (adult outpatient).</li>
      <li>Mastoiditis: Ceftriaxone 2 g IV q24h; ENT consult for drainage; 10‚Äì14 days.</li>
      <li>Otitis media: Amoxicillin 500 mg PO q8h √ó5‚Äì7 days (adjust for pediatrics).</li>
    </ul>
  </div>

  <button class="collapsible">Respiratory</button>
  <div class="panel">
    <ul>
      <li>CAP (inpatient non-ICU): Ceftriaxone 2 g IV q24h + Azithro 500 mg IV/PO day1 then 250 mg daily √ó5‚Äì7 d.</li>
      <li>HAP/VAP: Anti-pseudomonal Œ≤-lactam ¬± MRSA agent; 7 days if good response.</li>
      <li>Aspiration pneumonia: cover anaerobes (ampicillin-sulbactam or pip-tazo).</li>
    </ul>
  </div>

  <button class="collapsible">Urinary Tract</button>
  <div class="panel">
    <ul>
      <li>Uncomplicated cystitis: Nitrofurantoin 100 mg PO BID √ó5 days (if susceptible).</li>
      <li>Pyelonephritis (inpatient): Ceftriaxone 1‚Äì2 g IV q24h or Pip-tazo 4.5 g IV q6‚Äì8h; 7‚Äì14 days depending on severity.</li>
      <li>Catheter-associated UTI: Remove/replace catheter and treat per culture.</li>
    </ul>
  </div>

  <button class="collapsible">Intra-abdominal</button>
  <div class="panel">
    <ul>
      <li>Complicated IAI: Pip-tazo 4.5 g IV q6‚Äì8h or meropenem 1 g IV q8h; drainage of abscesses; 4‚Äì14 days depending on source control.</li>
      <li>Appendicitis prophylaxis: Single pre-op cefazolin 2 g IV (add metronidazole if contamination).</li>
    </ul>
  </div>

  <button class="collapsible">Skin & Soft Tissue</button>
  <div class="panel">
    <ul>
      <li>Non-purulent cellulitis: Cefazolin 1‚Äì2 g IV q8h (switch to oral cephalexin when improving) ‚Äî 5‚Äì7 days.</li>
      <li>Purulent SSTI: I&D; TMP-SMX or doxycycline if MRSA suspected.</li>
      <li>Necrotizing fasciitis: Broad-spectrum (vancomycin + pip-tazo or carbapenem) + urgent surgical debridement.</li>
    </ul>
  </div>

  <button class="collapsible">Bone & Joint</button>
  <div class="panel">
    <ul>
      <li>Osteomyelitis: Empiric vancomycin ¬± ceftriaxone pending cultures; 4‚Äì6+ weeks therapy guided by ID.</li>
      <li>Septic arthritis: Drainage + empiric vancomycin ¬± GN coverage; 2‚Äì4 weeks therapy.</li>
    </ul>
  </div>
</section>

<!-- HIGH-YIELD SYNDROMES -->
<section id="high-yield-syndromes">
  <h2>High-Yield Syndromes</h2>
  <p class="muted">Detailed management for common hospitalist infectious disease scenarios.</p>

  <button class="collapsible">Infective Endocarditis</button>
  <div class="panel">
    <h4>Modified Duke Criteria (2023 ESC Update)</h4>
    <p><strong>Definite IE:</strong> 2 major, OR 1 major + 3 minor, OR 5 minor criteria</p>
    <p><strong>Major Criteria:</strong></p>
    <ul>
      <li><strong>Blood cultures:</strong> Typical organisms (S. aureus, viridans strep, S. gallolyticus, HACEK, Enterococcus) from 2 separate cultures; OR persistently positive cultures 12h apart; OR ‚â•3 positive cultures over >1h</li>
      <li><strong>Imaging:</strong> Vegetation, abscess, pseudoaneurysm, dehiscence, or new valve regurgitation on echo; OR abnormal activity on 18F-FDG PET/CT (prosthetic) or cardiac CT showing abscess/pseudoaneurysm</li>
    </ul>
    <p><strong>Minor Criteria:</strong></p>
    <ul>
      <li>Predisposition (IVDU, prosthetic valve, prior IE, structural heart disease)</li>
      <li>Fever ‚â•38¬∞C</li>
      <li>Vascular phenomena (emboli, mycotic aneurysm, Janeway lesions, conjunctival hemorrhage)</li>
      <li>Immunologic phenomena (Osler nodes, Roth spots, glomerulonephritis, positive RF)</li>
      <li>Microbiologic evidence not meeting major criteria</li>
    </ul>

    <h4>Empiric Therapy (Before Culture Results)</h4>
    <table>
      <tr><th>Scenario</th><th>Regimen</th><th>Notes</th></tr>
      <tr><td>Native valve, community-acquired</td><td>Vancomycin + Ceftriaxone</td><td>Covers MSSA, MRSA, strep, enterococcus</td></tr>
      <tr><td>Native valve, IVDU</td><td>Vancomycin + Ceftriaxone</td><td>High MRSA prevalence; add gentamicin if critically ill</td></tr>
      <tr><td>Prosthetic valve (early <1yr)</td><td>Vancomycin + Gentamicin + Rifampin + Cefepime</td><td>Cover staph, GNR, enterococcus</td></tr>
      <tr><td>Prosthetic valve (late >1yr)</td><td>Vancomycin + Ceftriaxone</td><td>Similar to native valve</td></tr>
    </table>

    <h4>Duration by Organism & Valve</h4>
    <table>
      <tr><th>Organism</th><th>Native Valve</th><th>Prosthetic Valve</th></tr>
      <tr><td>Streptococci (MIC ‚â§0.12)</td><td>4 weeks (2 wks if + gent)</td><td>6 weeks</td></tr>
      <tr><td>Enterococcus</td><td>4-6 weeks (+ gent synergy)</td><td>6 weeks minimum</td></tr>
      <tr><td>Staphylococcus (MSSA)</td><td>6 weeks</td><td>‚â•6 weeks + rifampin + gent √ó 2wks</td></tr>
      <tr><td>Staphylococcus (MRSA)</td><td>6 weeks vanc</td><td>‚â•6 weeks + rifampin + gent √ó 2wks</td></tr>
      <tr><td>HACEK</td><td>4 weeks</td><td>6 weeks</td></tr>
    </table>

    <h4>Surgical Indications</h4>
    <ul>
      <li><strong>Emergent (within 24h):</strong> Refractory pulmonary edema, cardiogenic shock from severe AI/MR</li>
      <li><strong>Urgent (within days):</strong> Uncontrolled infection despite abx, abscess, enlarging vegetation, persistent bacteremia >7d, fungal IE</li>
      <li><strong>Elective:</strong> Large vegetation >10mm with embolic event, severe valve dysfunction once stabilized</li>
    </ul>
  </div>

  <button class="collapsible">Bacterial Meningitis</button>
  <div class="panel">
    <h4>Empiric Therapy by Age/Risk</h4>
    <table>
      <tr><th>Population</th><th>Likely Pathogens</th><th>Empiric Regimen</th></tr>
      <tr><td>Adults 18-50</td><td>S. pneumoniae, N. meningitidis</td><td>Ceftriaxone 2g IV q12h + Vancomycin 15-20mg/kg IV q8-12h</td></tr>
      <tr><td>Adults >50 or immunocompromised</td><td>+ Listeria monocytogenes</td><td>Above + Ampicillin 2g IV q4h</td></tr>
      <tr><td>Neurosurgery/head trauma/CSF shunt</td><td>S. aureus, GNR, Pseudomonas</td><td>Vancomycin + Cefepime 2g IV q8h (or Meropenem)</td></tr>
    </table>

    <h4>Dexamethasone</h4>
    <ul>
      <li><strong>Indication:</strong> Give BEFORE or WITH first antibiotic dose if bacterial meningitis suspected</li>
      <li><strong>Dose:</strong> Dexamethasone 0.15 mg/kg IV q6h √ó 4 days</li>
      <li><strong>Benefit:</strong> Reduces mortality and hearing loss in pneumococcal meningitis; less clear for other organisms</li>
      <li><strong>Discontinue if:</strong> CSF gram stain/culture shows non-pneumococcal organism (some experts continue regardless)</li>
    </ul>

    <h4>CSF Interpretation</h4>
    <table>
      <tr><th>Parameter</th><th>Bacterial</th><th>Viral</th><th>TB/Fungal</th></tr>
      <tr><td>WBC</td><td>>1000 (often >5000)</td><td>10-500</td><td>50-500</td></tr>
      <tr><td>Differential</td><td>>80% PMN</td><td>Lymphocyte predominant</td><td>Lymphocyte predominant</td></tr>
      <tr><td>Glucose</td><td><40 mg/dL (or CSF:serum <0.4)</td><td>Normal</td><td>Low</td></tr>
      <tr><td>Protein</td><td>>200 mg/dL</td><td>50-100</td><td>100-500</td></tr>
      <tr><td>Opening pressure</td><td>Elevated (>20 cmH2O)</td><td>Normal/mild ‚Üë</td><td>Often elevated</td></tr>
    </table>
    <p><strong>Pearl:</strong> Early bacterial meningitis or partially treated may show lymphocyte predominance. Repeat LP in 12-24h if uncertain.</p>
  </div>

  <button class="collapsible">Necrotizing Fasciitis</button>
  <div class="panel">
    <h4>Key Principles</h4>
    <ul>
      <li><strong>SURGICAL EMERGENCY:</strong> Mortality increases 7-9% for every hour of delay in debridement</li>
      <li><strong>Types:</strong> Type I (polymicrobial, diabetics/elderly), Type II (Group A Strep or S. aureus monomicrobial)</li>
      <li><strong>Clinical clues:</strong> Pain out of proportion, rapid progression, crepitus, bullae, skin necrosis, systemic toxicity</li>
    </ul>

    <h4>LRINEC Score (Laboratory Risk Indicator for Necrotizing Fasciitis)</h4>
    <table>
      <tr><th>Variable</th><th>Value</th><th>Points</th></tr>
      <tr><td>CRP</td><td>‚â•150 mg/L</td><td>4</td></tr>
      <tr><td>WBC</td><td>15-25</td><td>1</td></tr>
      <tr><td>WBC</td><td>>25</td><td>2</td></tr>
      <tr><td>Hemoglobin</td><td>11-13.5 g/dL</td><td>1</td></tr>
      <tr><td>Hemoglobin</td><td><11 g/dL</td><td>2</td></tr>
      <tr><td>Sodium</td><td><135 mEq/L</td><td>2</td></tr>
      <tr><td>Creatinine</td><td>>1.6 mg/dL</td><td>2</td></tr>
      <tr><td>Glucose</td><td>>180 mg/dL</td><td>1</td></tr>
    </table>
    <p><strong>Interpretation:</strong> ‚â•6 = high suspicion (PPV 92%); ‚â•8 = strongly predictive. But <strong>do NOT use to rule out</strong>‚Äîlow score doesn't exclude nec fasc!</p>

    <h4>Empiric Therapy</h4>
    <ul>
      <li><strong>Broad-spectrum:</strong> Vancomycin + Piperacillin-tazobactam (or Meropenem) + Clindamycin</li>
      <li><strong>Clindamycin rationale:</strong> Inhibits toxin production (Eagle effect‚Äîsevere GAS may not respond to beta-lactams alone in high inoculum)</li>
      <li><strong>Duration:</strong> Continue until debridements complete, clinically stable, cultures guide de-escalation</li>
    </ul>

    <h4>Surgical Principles</h4>
    <ul>
      <li>OR within 12-24 hours of presentation (ideally within 6h)</li>
      <li>Finger test: If tissue planes dissect easily with blunt finger, confirms diagnosis</li>
      <li>Repeat debridement every 24-48h until clean margins</li>
      <li>Consider IVIG for streptococcal toxic shock (2g/kg single dose)</li>
    </ul>
  </div>

  <button class="collapsible">Diabetic Foot Infections</button>
  <div class="panel">
    <h4>IDSA/IWGDF Classification</h4>
    <table>
      <tr><th>Grade</th><th>Clinical Features</th><th>Management</th></tr>
      <tr><td><strong>1 - Uninfected</strong></td><td>Wound without signs of infection</td><td>Wound care, offloading</td></tr>
      <tr><td><strong>2 - Mild</strong></td><td>Local infection, erythema ‚â§2cm from wound, limited to skin/subQ</td><td>Oral abx, outpatient (1-2 weeks)</td></tr>
      <tr><td><strong>3 - Moderate</strong></td><td>Erythema >2cm, or deeper than skin/subQ (abscess, fascia, muscle, bone, joint)</td><td>IV abx, hospitalize, surgical eval (2-4 weeks)</td></tr>
      <tr><td><strong>4 - Severe</strong></td><td>Local infection + SIRS (fever, HR >90, RR >20, WBC >12k or <4k)</td><td>IV abx, hospitalize, urgent surgery (2-4 weeks)</td></tr>
    </table>

    <h4>Microbiology</h4>
    <ul>
      <li><strong>Acute, mild:</strong> Often gram-positive (S. aureus, Strep)</li>
      <li><strong>Chronic, severe, prior abx:</strong> Polymicrobial‚Äîadd GNR, Pseudomonas, anaerobes</li>
      <li><strong>Always culture:</strong> Deep tissue or bone, not superficial swab</li>
    </ul>

    <h4>Empiric Antibiotic Selection</h4>
    <table>
      <tr><th>Severity</th><th>No MRSA/Pseudomonas Risk</th><th>MRSA/Pseudomonas Risk</th></tr>
      <tr><td>Mild</td><td>Amoxicillin-clavulanate OR TMP-SMX + Amoxicillin</td><td>TMP-SMX or Doxycycline</td></tr>
      <tr><td>Moderate</td><td>Ampicillin-sulbactam OR Ceftriaxone + Metronidazole</td><td>Vancomycin + Ceftazidime or Pip-Tazo</td></tr>
      <tr><td>Severe</td><td>Piperacillin-tazobactam</td><td>Vancomycin + Piperacillin-tazobactam (or Meropenem)</td></tr>
    </table>

    <h4>Osteomyelitis Considerations</h4>
    <ul>
      <li><strong>Probe-to-bone test:</strong> If sterile probe reaches bone through ulcer ‚Üí 87% PPV for osteo</li>
      <li><strong>MRI:</strong> Most sensitive/specific imaging; get if probe positive or high clinical suspicion</li>
      <li><strong>Duration:</strong> 4-6 weeks if residual infected bone; may be shorter if complete resection</li>
    </ul>

    <h4>Amputation Considerations</h4>
    <ul>
      <li>Unreconstructable vascular disease with tissue loss</li>
      <li>Uncontrolled sepsis despite debridement</li>
      <li>Non-functional limb even if infection controlled</li>
      <li>Extensive tissue necrosis beyond salvage</li>
      <li>Patient preference (especially if prolonged treatment/disability expected)</li>
    </ul>
  </div>

  <button class="collapsible">Prosthetic Joint Infection (PJI)</button>
  <div class="panel">
    <h4>MSIS Criteria (2018 Definition)</h4>
    <p><strong>Definite PJI:</strong> ‚â•1 major criterion OR ‚â•3 minor criteria (‚â•6 points)</p>
    <p><strong>Major Criteria (diagnostic):</strong></p>
    <ul>
      <li>Two positive periprosthetic cultures with identical organism</li>
      <li>Sinus tract communicating with joint</li>
    </ul>
    <p><strong>Minor Criteria (weighted scoring):</strong></p>
    <table>
      <tr><th>Criterion</th><th>Points</th></tr>
      <tr><td>Elevated serum CRP (>10 mg/L) AND ESR (>30)</td><td>2</td></tr>
      <tr><td>Elevated synovial WBC (>3000) OR ++ leukocyte esterase</td><td>3</td></tr>
      <tr><td>Elevated synovial PMN% (>80%)</td><td>2</td></tr>
      <tr><td>Single positive culture</td><td>2</td></tr>
      <tr><td>Positive histopathology</td><td>3</td></tr>
    </table>

    <h4>Treatment Strategy</h4>
    <table>
      <tr><th>Scenario</th><th>Strategy</th></tr>
      <tr><td>Acute (<4 wks from implant) or acute hematogenous (<3 wks symptoms)</td><td>DAIR (Debridement, Antibiotics, Implant Retention) + 6 weeks IV then oral suppression</td></tr>
      <tr><td>Chronic (>4 wks from implant, >3 wks symptoms)</td><td>Two-stage exchange (spacer with abx cement, 6+ wks abx, then reimplant)</td></tr>
      <tr><td>Highly virulent/difficult organism (MRSA, resistant GNR)</td><td>Two-stage exchange preferred</td></tr>
    </table>

    <h4>Antibiotic Principles</h4>
    <ul>
      <li><strong>Staph:</strong> Add rifampin (biofilm activity) once wound stable; use with companion drug (quinolone, TMP-SMX)</li>
      <li><strong>Duration:</strong> 6 weeks for hip, 12 weeks for knee (if DAIR); may extend for two-stage</li>
      <li><strong>Suppressive therapy:</strong> May be lifelong if implant retained and high risk of relapse</li>
    </ul>
  </div>

  <button class="collapsible">CLABSI (Central Line-Associated Bloodstream Infection)</button>
  <div class="panel">
    <h4>Definition (NHSN/CDC)</h4>
    <ul>
      <li>Central line in place >2 days AND on day of or day before BSI</li>
      <li>Blood culture positive for recognized pathogen OR common commensal from ‚â•2 separate cultures</li>
      <li>No other apparent source</li>
    </ul>

    <h4>Common Pathogens</h4>
    <ul>
      <li>Coagulase-negative Staphylococci (most common)</li>
      <li>S. aureus (MSSA & MRSA)</li>
      <li>Enterococcus</li>
      <li>Candida species</li>
      <li>Gram-negative rods (Klebsiella, E. coli, Pseudomonas, Enterobacter)</li>
    </ul>

    <h4>Management by Organism</h4>
    <table>
      <tr><th>Organism</th><th>Line Removal</th><th>Duration</th></tr>
      <tr><td>S. aureus</td><td><strong>REMOVE</strong> (always)</td><td>4-6 weeks if complicated; 2 weeks if uncomplicated, TEE negative</td></tr>
      <tr><td>Candida</td><td><strong>REMOVE</strong> (always)</td><td>14 days from first negative culture</td></tr>
      <tr><td>Pseudomonas</td><td><strong>REMOVE</strong></td><td>7-14 days</td></tr>
      <tr><td>Enterococcus</td><td>Remove recommended</td><td>7-14 days</td></tr>
      <tr><td>Coag-neg Staph</td><td>May salvage with abx lock therapy</td><td>5-7 days if line removed; 10-14 days if retained</td></tr>
      <tr><td>GNR (non-Pseudomonas)</td><td>Attempt salvage possible</td><td>7-14 days</td></tr>
    </table>

    <h4>Complicated CLABSI (Requires Longer Therapy)</h4>
    <ul>
      <li>Persistent bacteremia >72h despite appropriate therapy and line removal</li>
      <li>Endocarditis (get TTE, consider TEE especially for S. aureus)</li>
      <li>Septic thrombophlebitis</li>
      <li>Osteomyelitis or metastatic infection</li>
    </ul>
  </div>

  <button class="collapsible">Spinal Epidural Abscess</button>
  <div class="panel">
    <h4>Classic Triad (present in <15%)</h4>
    <ul>
      <li>Fever</li>
      <li>Back pain (most common presenting symptom‚Äî95%)</li>
      <li>Neurologic deficit (late finding)</li>
    </ul>

    <h4>Risk Factors</h4>
    <ul>
      <li>IVDU, diabetes, immunosuppression, alcoholism</li>
      <li>Recent spinal procedure or epidural catheter</li>
      <li>Distant infection (bacteremia, skin/soft tissue)</li>
      <li>Degenerative spine disease</li>
    </ul>

    <h4>Diagnosis</h4>
    <ul>
      <li><strong>MRI with gadolinium:</strong> Imaging of choice‚Äîentire spine if clinical localization unclear</li>
      <li><strong>Blood cultures:</strong> Positive in 60-70%</li>
      <li><strong>Labs:</strong> Elevated WBC, ESR (usually >30), CRP</li>
    </ul>

    <h4>Microbiology</h4>
    <ul>
      <li>S. aureus: 60-70% (MRSA common)</li>
      <li>Gram-negative rods: 15% (especially with UTI source)</li>
      <li>Streptococci: 10%</li>
      <li>TB: Consider in endemic areas or immunocompromised</li>
    </ul>

    <h4>Management</h4>
    <ul>
      <li><strong>Empiric:</strong> Vancomycin + Ceftriaxone (or Cefepime if Pseudomonas risk)</li>
      <li><strong>Surgery:</strong> Urgent decompression if neurologic deficits or progression, failure of medical therapy, or instability</li>
      <li><strong>Medical management alone:</strong> Consider if no neuro deficits, small abscess, high surgical risk, improving on abx</li>
      <li><strong>Duration:</strong> 6-8 weeks IV (longer if vertebral osteomyelitis)</li>
    </ul>

    <h4>Prognosis</h4>
    <ul>
      <li>Neurologic outcome correlates with severity and duration of deficits pre-op</li>
      <li>Paralysis >24-48 hours rarely recovers‚Äîemphasizes urgency</li>
    </ul>
  </div>

  <button class="collapsible">Febrile Neutropenia</button>
  <div class="panel">
    <h4>Definitions</h4>
    <ul>
      <li><strong>Fever:</strong> Single temp ‚â•38.3¬∞C OR ‚â•38.0¬∞C sustained for ‚â•1 hour</li>
      <li><strong>Neutropenia:</strong> ANC <500/¬µL OR <1000/¬µL with expected decline to <500 within 48h</li>
      <li><strong>Profound neutropenia:</strong> ANC <100/¬µL</li>
      <li><strong>Prolonged neutropenia:</strong> Expected >7 days</li>
    </ul>

    <h4>MASCC Risk Index (Multinational Association for Supportive Care in Cancer)</h4>
    <table>
      <tr><th>Characteristic</th><th>Points</th></tr>
      <tr><td>Burden of illness: Mild or no symptoms</td><td>5</td></tr>
      <tr><td>Burden of illness: Moderate symptoms</td><td>3</td></tr>
      <tr><td>No hypotension (SBP ‚â•90)</td><td>5</td></tr>
      <tr><td>No COPD</td><td>4</td></tr>
      <tr><td>Solid tumor or no prior fungal infection</td><td>4</td></tr>
      <tr><td>Outpatient at fever onset</td><td>3</td></tr>
      <tr><td>No dehydration</td><td>3</td></tr>
      <tr><td>Age <60 years</td><td>2</td></tr>
    </table>
    <p><strong>Score ‚â•21:</strong> Low risk‚Äîmay consider outpatient oral therapy (quinolone + amoxicillin-clavulanate)</p>
    <p><strong>Score <21:</strong> High risk‚Äîrequires inpatient IV therapy</p>

    <h4>Empiric Therapy</h4>
    <table>
      <tr><th>Risk</th><th>Regimen</th></tr>
      <tr><td>Standard (high-risk)</td><td>Cefepime 2g IV q8h OR Piperacillin-tazobactam 4.5g IV q6h OR Meropenem 1g IV q8h</td></tr>
      <tr><td>+ MRSA risk factors</td><td>Add Vancomycin (hemodynamic instability, skin/catheter infection, pneumonia, known MRSA colonization)</td></tr>
      <tr><td>+ Pseudomonas risk</td><td>Use anti-pseudomonal beta-lactam (cefepime, pip-tazo, meropenem)</td></tr>
      <tr><td>Low risk (outpatient)</td><td>Ciprofloxacin 750mg PO q12h + Amoxicillin-clavulanate 875mg PO q12h</td></tr>
    </table>

    <h4>Add Antifungal If:</h4>
    <ul>
      <li>Persistent fever >4-7 days despite broad-spectrum antibiotics</li>
      <li>Prolonged neutropenia (>10 days expected)</li>
      <li>Hematologic malignancy or HSCT recipient</li>
      <li><strong>Options:</strong> Caspofungin, Micafungin, Liposomal Amphotericin B, Voriconazole (if Aspergillus suspected)</li>
    </ul>

    <h4>Duration</h4>
    <ul>
      <li>Continue until ANC ‚â•500 AND afebrile for 48h (if source unidentified)</li>
      <li>If documented infection, complete appropriate course for that infection</li>
    </ul>
  </div>
</section>

<!-- SEPSIS -->
<section id="sepsis">
  <h2>Sepsis</h2>

  <button class="collapsible">Immediate Actions (Sepsis Bundle)</button>
  <div class="panel">
    <ul>
      <li>Obtain cultures (blood √ó2, site-specific) before antibiotics if feasible ‚Äî do not delay critical therapy.</li>
      <li>Administer broad-spectrum IV antibiotics within 1 hour.</li>
      <li>Give 30 mL/kg crystalloid bolus for hypotension or lactate ‚â•4 mmol/L.</li>
      <li>Start vasopressors (norepinephrine preferred) to maintain MAP ‚â•65 mmHg if hypotension persists.</li>
      <li>Reassess daily; de-escalate when appropriate.</li>
    </ul>
  </div>

  <button class="collapsible">Complications & Monitoring</button>
  <div class="panel">
    <ul>
      <li>Monitor lactate, urine output, mental status, organ function.</li>
      <li>Adjust dosing in renal/hepatic failure and ECMO/CRRT settings.</li>
    </ul>
  </div>
</section>

<!-- PATHOGEN GUIDANCE -->
<section id="pathogen-guidance">
  <h2>Pathogen-Based Guidance (Quick)</h2>

  <button class="collapsible">Gram-Positive Cocci</button>
  <div class="panel">
    <ul>
      <li>MSSA: Anti-staphylococcal penicillins (nafcillin/oxacillin) or cefazolin.</li>
      <li>MRSA: Vancomycin (AUC-based), alternatives: daptomycin (not for pneumonia), linezolid (pneumonia option).</li>
      <li>Enterococcus: Ampicillin if susceptible; VRE ‚Üí linezolid or daptomycin (dose per weight).</li>
    </ul>
  </div>

  <button class="collapsible">Gram-Negative Rods</button>
  <div class="panel">
    <ul>
      <li>Enterobacteriaceae: ceftriaxone/cefepime/pip-tazo; escalate to carbapenem for ESBL.</li>
      <li>Pseudomonas: cefepime/meropenem/pip-tazo; consider aminoglycoside synergy in severe cases.</li>
      <li>Burkholderia: often multidrug-resistant; use ceftazidime/meropenem/TMP-SMX guided by susceptibilities.</li>
    </ul>
  </div>

  <button class="collapsible">Anaerobes</button>
  <div class="panel">
    <ul>
      <li>Bacteroides: metronidazole with beta-lactam partner, or beta-lactam/beta-lactamase inhibitor; carbapenems for severe disease.</li>
      <li>Actinomyces: prolonged high-dose penicillin therapy (months).</li>
    </ul>
  </div>

  <button class="collapsible">Intracellular/Fastidious</button>
  <div class="panel">
    <ul>
      <li>Legionella: fluoroquinolone or macrolide.</li>
      <li>Chlamydia: doxycycline or macrolide.</li>
      <li>Nocardia: TMP-SMX (often high-dose), alternatives include linezolid, imipenem guided by susceptibility.</li>
    </ul>
  </div>
</section>

<!-- PATHOGEN OVERVIEW -->
<section id="pathogen-overview">
  <h2>Pathogen Overview ‚Äî Selected Genera (expanded)</h2>

  <button class="collapsible">Escherichia coli</button>
  <div class="panel">
    <ul>
      <li>Gram-negative rod; common cause of UTI, intra-abdominal infection, bacteremia.</li>
      <li>ESBL prevalence variable ‚Äî check local antibiogram; resistant isolates often require carbapenem.</li>
      <li>Virulence: adhesins, endotoxin; therapy guided by susceptibility.</li>
    </ul>
  </div>

  <button class="collapsible">Klebsiella spp.</button>
  <div class="panel">
    <ul>
      <li>Encapsulated gram-negative rod; causes pneumonia, UTI, liver abscess.</li>
      <li>Carbapenemase producers (KPC, NDM) are significant ‚Äî infection control & ID consultation recommended.</li>
    </ul>
  </div>

  <button class="collapsible">Pseudomonas aeruginosa</button>
  <div class="panel">
    <ul>
      <li>Non-fermenter; common in HAP/VAP, wound infections, device-related infections.</li>
      <li>Resistance via efflux pumps, porin loss, beta-lactamases; biofilms complicate device infections.</li>
      <li>Therapy: higher dosing, extended infusions of beta-lactams often beneficial; tailor to MICs.</li>
    </ul>
  </div>

  <button class="collapsible">Burkholderia cepacia complex</button>
  <div class="panel">
    <ul>
      <li>Important in cystic fibrosis and immunocompromised hosts; often intrinsically resistant.</li>
      <li>Combination therapy frequently required; consult susceptibility/ID.</li>
    </ul>
  </div>

  <button class="collapsible">Bacteroides fragilis</button>
  <div class="panel">
    <ul>
      <li>Anaerobic gram-negative rod common in intra-abdominal infections; beta-lactamase production common.</li>
      <li>Prefer agents with anaerobic coverage: metronidazole, beta-lactam/beta-lactamase inhibitors, carbapenems.</li>
    </ul>
  </div>

  <button class="collapsible">Actinomyces</button>
  <div class="panel">
    <ul>
      <li>Filamentous, gram-positive anaerobe associated with dental disease and cervicofacial infections.</li>
      <li>Treatment: prolonged high-dose penicillin (months), surgical drainage when required.</li>
    </ul>
  </div>

  <button class="collapsible">Mycobacterium tuberculosis (brief)</button>
  <div class="panel">
    <ul>
      <li>Acid-fast bacillus; RIPE therapy (rifampin, isoniazid, pyrazinamide, ethambutol) initial phase.</li>
      <li>Diagnosis and management require public health and specialist involvement due to public health implications and prolonged therapy.</li>
    </ul>
  </div>

  <button class="collapsible">Nocardia</button>
  <div class="panel">
    <ul>
      <li>Branching, weakly acid-fast filamentous bacterium; pulmonary, disseminated and CNS disease seen in immunocompromised.</li>
      <li>Treatment: TMP-SMX backbone; duration 6‚Äì12 months depending on site; consider linezolid/imipenem depending on species.</li>
    </ul>
  </div>

  <button class="collapsible">Clostridioides difficile</button>
  <div class="panel">
    <ul>
      <li>Spore-forming anaerobe causing antibiotic-associated colitis; severe disease may cause toxic megacolon.</li>
      <li>Treatment: oral vancomycin or fidaxomicin for initial episode; fecal microbiota transplant for recurrent disease per guidelines.</li>
    </ul>
  </div>

  <!-- Additional High-Yield Pathogens -->
  <button class="collapsible">VRE (Vancomycin-Resistant Enterococcus)</button>
  <div class="panel">
    <ul>
      <li><strong>Species:</strong> Primarily E. faecium (vanA, vanB genes); E. faecalis less common</li>
      <li><strong>Risk factors:</strong> Prior vancomycin, prolonged hospitalization, ICU, immunosuppression, GI colonization</li>
      <li><strong>Treatment:</strong>
        <ul>
          <li>Linezolid 600mg IV/PO q12h (preferred for many infections, oral bioavailability 100%)</li>
          <li>Daptomycin 6-8 mg/kg IV daily (higher doses for bacteremia 8-12 mg/kg; NOT for pneumonia)</li>
          <li>Tigecycline (for intra-abdominal/skin only; poor serum levels)</li>
        </ul>
      </li>
      <li><strong>Duration:</strong> UTI 5-7 days; bacteremia 7-14 days; endocarditis 6 weeks (ID consult)</li>
      <li><strong>Pearl:</strong> VRE bacteremia‚Äîremove lines if present; search for intra-abdominal/biliary source</li>
    </ul>
  </div>

  <button class="collapsible">ESBL Producers (Extended-Spectrum Beta-Lactamase)</button>
  <div class="panel">
    <ul>
      <li><strong>Organisms:</strong> E. coli, Klebsiella pneumoniae, Proteus mirabilis most common</li>
      <li><strong>Resistance pattern:</strong> Resistant to 3rd-gen cephalosporins (ceftriaxone, ceftazidime), aztreonam; often co-resistant to fluoroquinolones, TMP-SMX</li>
      <li><strong>Risk factors:</strong> Prior 3rd-gen cephalosporin or fluoroquinolone use, healthcare exposure, travel to endemic areas (India, Middle East)</li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>Severe infections/bacteremia:</strong> Meropenem 1g IV q8h or Ertapenem 1g IV daily (carbapenems are treatment of choice)</li>
          <li><strong>UTI (uncomplicated):</strong> May use nitrofurantoin, fosfomycin if susceptible; TMP-SMX if susceptible</li>
          <li><strong>Pip-tazo:</strong> May be used if MIC ‚â§16 and non-critically ill (controversial‚ÄîMERINO trial suggests carbapenem superiority for bacteremia)</li>
        </ul>
      </li>
      <li><strong>Pearl:</strong> Always confirm susceptibilities; report may show cephalosporin "susceptible" but clinical failure can occur</li>
    </ul>
  </div>

  <button class="collapsible">CRE (Carbapenem-Resistant Enterobacteriaceae)</button>
  <div class="panel">
    <ul>
      <li><strong>Organisms:</strong> K. pneumoniae (KPC most common in US), E. coli, Enterobacter</li>
      <li><strong>Mechanisms:</strong> KPC (Klebsiella pneumoniae carbapenemase), NDM, OXA-48, VIM, IMP</li>
      <li><strong>Risk factors:</strong> Prior carbapenems, prolonged hospitalization, ICU, mechanical ventilation, international travel (NDM‚ÄîSouth Asia)</li>
      <li><strong>Treatment (ID consult strongly recommended):</strong>
        <ul>
          <li><strong>Ceftazidime-avibactam:</strong> 2.5g IV q8h‚Äîcovers KPC and OXA-48 (NOT NDM)</li>
          <li><strong>Meropenem-vaborbactam:</strong> 4g IV q8h‚Äîcovers KPC</li>
          <li><strong>Imipenem-relebactam:</strong> Alternative for KPC</li>
          <li><strong>Cefiderocol:</strong> Siderophore cephalosporin‚Äîcovers NDM, difficult GNRs</li>
          <li><strong>Combination therapy:</strong> Consider for severe infections (e.g., high-dose meropenem + polymyxin or aminoglycoside)</li>
        </ul>
      </li>
      <li><strong>Mortality:</strong> 40-50% for CRE bacteremia‚Äîhighlights severity</li>
      <li><strong>Infection control:</strong> Contact precautions, aggressive screening, single rooms</li>
    </ul>
  </div>

  <button class="collapsible">Acinetobacter baumannii</button>
  <div class="panel">
    <ul>
      <li><strong>Characteristics:</strong> Gram-negative coccobacillus, environmental persistence, rapid resistance development</li>
      <li><strong>Clinical syndromes:</strong> VAP (most common), CLABSI, wound infections, meningitis (post-neurosurgical)</li>
      <li><strong>Risk factors:</strong> ICU, mechanical ventilation, prior broad-spectrum antibiotics, wounds/burns, deployed military</li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>MDR Acinetobacter:</strong> Ampicillin-sulbactam (high dose 9g IV q8h‚Äîsulbactam has intrinsic activity)</li>
          <li><strong>XDR/pan-resistant:</strong> Polymyxin B or Colistin (often in combination)</li>
          <li><strong>Sulbactam-durlobactam (Xacduro):</strong> Newly approved for hospital-acquired pneumonia</li>
          <li><strong>Tigecycline:</strong> May be used for non-bacteremic infections (achieves poor serum levels)</li>
          <li><strong>Combination therapy:</strong> Often used for severe infections (carbapenem + polymyxin if any susceptibility)</li>
        </ul>
      </li>
      <li><strong>Pearl:</strong> Colonization vs. infection distinction important‚Äîmay not need treatment if just colonizing respiratory tract</li>
    </ul>
  </div>

  <button class="collapsible">Stenotrophomonas maltophilia</button>
  <div class="panel">
    <ul>
      <li><strong>Characteristics:</strong> Intrinsically resistant to carbapenems (L1 and L2 beta-lactamases)</li>
      <li><strong>Clinical syndromes:</strong> Pneumonia (especially VAP), CLABSI, wound infections, often in immunocompromised/CF patients</li>
      <li><strong>Risk factors:</strong> Prior carbapenems, prolonged hospitalization, ICU, malignancy, steroids, CF</li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>First-line:</strong> TMP-SMX 15-20 mg/kg/day (TMP component) IV divided q6-8h</li>
          <li><strong>Alternatives:</strong> Levofloxacin, Minocycline, Ticarcillin-clavulanate, Ceftazidime-avibactam (check susceptibility)</li>
          <li><strong>Severe infections:</strong> Consider combination therapy (TMP-SMX + fluoroquinolone or minocycline)</li>
        </ul>
      </li>
      <li><strong>Duration:</strong> 7-14 days depending on source</li>
      <li><strong>Pearl:</strong> Do NOT use carbapenems‚Äîintrinsic resistance; monotherapy may select further resistance</li>
    </ul>
  </div>

  <button class="collapsible">Listeria monocytogenes</button>
  <div class="panel">
    <ul>
      <li><strong>Characteristics:</strong> Gram-positive rod, facultative intracellular, grows at refrigerator temps</li>
      <li><strong>Clinical syndromes:</strong> Meningitis, bacteremia, rhombencephalitis (brainstem), gastroenteritis, maternal-fetal infection</li>
      <li><strong>Risk factors:</strong> Age >50, pregnancy, immunocompromise (steroids, transplant, HIV), cirrhosis, diabetes, iron overload</li>
      <li><strong>Source:</strong> Contaminated food‚Äîdeli meats, soft cheeses, unpasteurized dairy, cantaloupe</li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>First-line:</strong> Ampicillin 2g IV q4h (¬± Gentamicin for synergy in severe/meningitis)</li>
          <li><strong>Penicillin allergy:</strong> TMP-SMX (Bactrim) 10-20 mg/kg/day TMP component</li>
          <li><strong>NOT susceptible to:</strong> Cephalosporins (important‚Äîwhy ampicillin added to meningitis empiric regimen in elderly)</li>
        </ul>
      </li>
      <li><strong>Duration:</strong> Bacteremia 2 weeks; meningitis 3+ weeks; rhombencephalitis/brain abscess 6+ weeks</li>
      <li><strong>Pearl:</strong> CSF may show mononuclear predominance and only mildly elevated protein‚Äîcan mimic viral/TB</li>
    </ul>
  </div>

  <button class="collapsible">Legionella pneumophila</button>
  <div class="panel">
    <ul>
      <li><strong>Characteristics:</strong> Gram-negative rod (stains poorly), obligate intracellular, environmental (water systems)</li>
      <li><strong>Clinical syndromes:</strong> Atypical pneumonia, Pontiac fever (self-limited febrile illness)</li>
      <li><strong>Risk factors:</strong> Smoking, COPD, immunosuppression, age >50, recent travel, hospital water exposure</li>
      <li><strong>Clinical clues:</strong> High fever, relative bradycardia, hyponatremia, diarrhea, confusion, elevated LFTs, low phosphorus</li>
      <li><strong>Diagnosis:</strong>
        <ul>
          <li><strong>Urine antigen:</strong> Serogroup 1 only (most common), 80% sensitive, 99% specific, remains positive for weeks</li>
          <li><strong>Respiratory culture:</strong> Requires special media (BCYE agar)‚Äîspecify Legionella if suspected</li>
          <li><strong>PCR:</strong> Increasingly available</li>
        </ul>
      </li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>Preferred:</strong> Levofloxacin 750mg IV/PO daily OR Azithromycin 500mg IV/PO daily</li>
          <li><strong>Severe/immunocompromised:</strong> Consider combination (fluoroquinolone + azithromycin) initially</li>
        </ul>
      </li>
      <li><strong>Duration:</strong> 5-10 days (mild); 14-21 days (severe/immunocompromised)</li>
    </ul>
  </div>

  <button class="collapsible">PJP (Pneumocystis jirovecii Pneumonia)</button>
  <div class="panel">
    <ul>
      <li><strong>Epidemiology:</strong> Fungal infection in immunocompromised‚ÄîHIV (CD4 <200), transplant, high-dose steroids, hematologic malignancy</li>
      <li><strong>Clinical:</strong> Subacute dyspnea (days to weeks), dry cough, fever, hypoxemia with exertion; desaturation with ambulation</li>
      <li><strong>Imaging:</strong> Bilateral interstitial/ground-glass infiltrates, often perihilar; can be normal early or atypical (nodules, cysts, pneumothorax)</li>
      <li><strong>Diagnosis:</strong>
        <ul>
          <li><strong>Induced sputum:</strong> 50-90% sensitive if available</li>
          <li><strong>BAL:</strong> >95% sensitive‚Äîgold standard</li>
          <li><strong>Beta-D-glucan:</strong> Elevated (>80 pg/mL), good negative predictive value</li>
          <li><strong>LDH:</strong> Typically elevated (non-specific)</li>
        </ul>
      </li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>First-line:</strong> TMP-SMX 15-20 mg/kg/day (TMP component) IV divided q6-8h √ó 21 days</li>
          <li><strong>Adjunctive steroids (if PaO2 <70 or A-a gradient >35):</strong> Prednisone 40mg PO BID √ó 5 days, then 40mg daily √ó 5, then 20mg daily √ó 11</li>
          <li><strong>Alternatives:</strong> Pentamidine IV, Atovaquone (mild), Clindamycin + Primaquine (moderate)</li>
        </ul>
      </li>
      <li><strong>Prophylaxis indications:</strong> HIV with CD4 <200, HSCT, high-dose steroids (‚â•20mg prednisone √ó 4+ weeks), certain chemo/biologics</li>
    </ul>
  </div>

  <button class="collapsible">CMV in Immunocompromised</button>
  <div class="panel">
    <ul>
      <li><strong>Populations:</strong> Transplant (SOT, HSCT), HIV (CD4 <50), high-dose steroids/biologics</li>
      <li><strong>Clinical syndromes:</strong> Colitis (diarrhea, bleeding), Pneumonitis, Retinitis, Hepatitis, Encephalitis</li>
      <li><strong>Diagnosis:</strong>
        <ul>
          <li><strong>CMV PCR (blood):</strong> Quantitative viral load‚Äîfor monitoring, rising VL suggests active disease</li>
          <li><strong>Tissue biopsy:</strong> Owl's eye inclusions, immunohistochemistry‚Äîgold standard for end-organ disease</li>
        </ul>
      </li>
      <li><strong>Treatment:</strong>
        <ul>
          <li><strong>Ganciclovir:</strong> 5 mg/kg IV q12h (induction 2-3 weeks), then 5 mg/kg IV daily (maintenance)</li>
          <li><strong>Valganciclovir:</strong> 900mg PO BID (induction), then 900mg PO daily‚Äîoral option if absorbing</li>
          <li><strong>Foscarnet:</strong> For ganciclovir-resistant CMV or if neutropenic; nephrotoxic, electrolyte wasting</li>
        </ul>
      </li>
      <li><strong>Monitoring:</strong> Weekly CMV PCR during treatment; toxicities (neutropenia, thrombocytopenia, renal for foscarnet)</li>
    </ul>
  </div>

  <button class="collapsible">HSV/VZV in Immunocompromised</button>
  <div class="panel">
    <ul>
      <li><strong>HSV Reactivation:</strong>
        <ul>
          <li>Mucocutaneous (oral, genital)‚Äîcan be severe, hemorrhagic, disseminated</li>
          <li>Esophagitis: Odynophagia, discrete ulcers on EGD</li>
          <li>Hepatitis: Rare, severe, high mortality</li>
          <li>Encephalitis: Even in immunocompetent‚Äîtemporal lobe</li>
        </ul>
      </li>
      <li><strong>HSV Treatment:</strong>
        <ul>
          <li><strong>Mucocutaneous:</strong> Acyclovir 400mg PO TID or Valacyclovir 1g BID √ó 7-14 days; IV if severe</li>
          <li><strong>Disseminated/Visceral:</strong> Acyclovir 10 mg/kg IV q8h √ó 14-21 days</li>
          <li><strong>Encephalitis:</strong> Acyclovir 10 mg/kg IV q8h √ó 14-21 days</li>
        </ul>
      </li>
      <li><strong>VZV Reactivation (Shingles):</strong>
        <ul>
          <li>Dermatomal vesicles on erythematous base; can disseminate in immunocompromised</li>
          <li>Complications: PHN, HZO (ophthalmic), Ramsay Hunt, meningoencephalitis, VZV vasculopathy</li>
        </ul>
      </li>
      <li><strong>VZV Treatment:</strong>
        <ul>
          <li><strong>Localized (immunocompetent):</strong> Valacyclovir 1g PO TID √ó 7 days</li>
          <li><strong>Immunocompromised or disseminated:</strong> Acyclovir 10 mg/kg IV q8h until no new lesions √ó 48h, then oral to complete 10-14 days</li>
        </ul>
      </li>
      <li><strong>Pearl:</strong> Adjust acyclovir for renal function; ensure adequate hydration (crystalluria risk)</li>
    </ul>
  </div>

  <button class="collapsible">MAC (Mycobacterium avium Complex)</button>
  <div class="panel">
    <ul>
      <li><strong>Epidemiology:</strong> Environmental NTM (water, soil); disease in HIV (CD4 <50), structural lung disease, bronchiectasis, CF</li>
      <li><strong>Clinical Syndromes:</strong>
        <ul>
          <li><strong>Disseminated (HIV):</strong> Fever, night sweats, weight loss, diarrhea, hepatosplenomegaly, cytopenias</li>
          <li><strong>Pulmonary (non-HIV):</strong> Chronic cough, nodular infiltrates, bronchiectasis (Lady Windermere syndrome‚ÄîRML/lingula)</li>
        </ul>
      </li>
      <li><strong>Diagnosis:</strong>
        <ul>
          <li><strong>Disseminated:</strong> Blood culture (isolator/lysis centrifugation), bone marrow biopsy</li>
          <li><strong>Pulmonary:</strong> ATS/IDSA criteria‚Äîsymptoms + imaging + microbiology (2+ sputum cultures OR 1 BAL OR tissue)</li>
        </ul>
      </li>
      <li><strong>Treatment (always multidrug):</strong>
        <ul>
          <li><strong>Core regimen:</strong> Azithromycin 250-500mg daily (or Clarithromycin) + Ethambutol 15 mg/kg daily + Rifampin (or Rifabutin for HIV)</li>
          <li><strong>Severe/disseminated:</strong> Add Amikacin or Streptomycin initially</li>
        </ul>
      </li>
      <li><strong>Duration:</strong> 12 months after culture-negative (pulmonary); lifelong suppression may be needed in HIV</li>
      <li><strong>Prophylaxis (HIV with CD4 <50):</strong> Azithromycin 1200mg weekly (less common now with effective ART)</li>
    </ul>
  </div>
</section>

<!-- ANTIBIOTIC CLASSES -->
<section id="antibiotic-classes">
  <h2>Antibiotic Classes & Escalation</h2>
  <table>
    <thead><tr><th>Class</th><th>Examples</th><th>Typical Use</th><th>Key Notes</th></tr></thead>
    <tbody>
      <tr><td>Penicillins</td><td>Amoxicillin, Ampicillin, Piperacillin-tazobactam</td><td>Strep, Enterococcus (amp), GN/anaerobes (pip-tazo)</td><td>Check allergy; renal adjust</td></tr>
      <tr><td>Cephalosporins</td><td>Cefazolin, Ceftriaxone, Cefepime</td><td>Varies by generation; cefepime for Pseudomonas</td><td>ESBL producers resistant</td></tr>
      <tr><td>Carbapenems</td><td>Meropenem, Imipenem</td><td>Broad GN including ESBL; severe polymicrobial</td><td>Reserve when possible</td></tr>
      <tr><td>Glycopeptides</td><td>Vancomycin</td><td>MRSA, serious GP infections</td><td>Monitor AUC/renal</td></tr>
      <tr><td>Oxazolidinones</td><td>Linezolid</td><td>VRE, MRSA alternatives</td><td>Thrombocytopenia risk, serotonin interactions</td></tr>
    </tbody>
  </table>
</section>

<!-- FUNGAL -->
<section id="fungal-infections">
  <h2>Fungal Infections</h2>

  <button class="collapsible">Candida (candidemia)</button>
  <div class="panel">
    <ul>
      <li>Empiric: Echinocandin (micafungin/caspofungin) IV for critically ill.</li>
      <li>Step-down: Fluconazole for susceptible species after clearance and ID consultation.</li>
      <li>Duration: 14 days after first negative blood culture if uncomplicated.</li>
    </ul>
  </div>

  <button class="collapsible">Aspergillus</button>
  <div class="panel">
    <ul>
      <li>Voriconazole first-line for invasive aspergillosis (weight-based IV dosing then PO); consider TDM.</li>
      <li>Liposomal amphotericin B for intolerance or certain species.</li>
    </ul>
  </div>

  <button class="collapsible">Cryptococcus</button>
  <div class="panel">
    <ul>
      <li>Induction: liposomal amphotericin B + flucytosine; consolidation/maintenance with fluconazole per guidelines.</li>
      <li>Consult ID for CNS disease and immunocompromised hosts.</li>
    </ul>
  </div>

  <button class="collapsible">Mucorales</button>
  <div class="panel">
    <ul>
      <li>Liposomal amphotericin B 5‚Äì10 mg/kg IV daily; urgent surgical debridement and control of underlying risk factors (e.g., hyperglycemia).</li>
    </ul>
  </div>
</section>

<!-- VIRAL -->
<section id="viral-infections">
  <h2>Viral Infections</h2>
  <table>
    <thead><tr><th>Virus</th><th>Therapy</th><th>Dose / Notes</th></tr></thead>
    <tbody>
      <tr><td>Influenza A/B</td><td>Oseltamivir</td><td>75 mg PO BID √ó5 d (longer if severe)</td></tr>
      <tr><td>HSV-1 / HSV-2 (severe/encephalitis)</td><td>Acyclovir</td><td>10 mg/kg IV q8h √ó14‚Äì21 d for encephalitis (adjust renal)</td></tr>
      <tr><td>CMV (organ-invasive)</td><td>Ganciclovir / Valganciclovir</td><td>Ganciclovir 5 mg/kg IV q12h induction; monitor counts</td></tr>
      <tr><td>RSV (severe)</td><td>Supportive / Ribavirin in select</td><td>Consider in transplant/infants per local protocols</td></tr>
    </tbody>
  </table>
  
  <button class="collapsible">Viral Hepatitis ‚Äî HAV, HBV, HCV, HDV, HEV</button>
  <div class="panel">
    <ul>
      <li><strong>Hepatitis A (HAV):</strong> Supportive care only; self-limited. Post-exposure prophylaxis for close contacts: HAV vaccine (age 1-40) or immunoglobulin.</li>
      <li><strong>Hepatitis B (Acute):</strong> Supportive care; 95% of adults clear spontaneously. Antivirals (tenofovir, entecavir) only if severe/protracted course, acute liver failure, or immunocompromised.</li>
      <li><strong>Hepatitis B (Chronic):</strong> Tenofovir disoproxil (TDF) 300 mg daily or Entecavir 0.5 mg daily (1 mg if lamivudine-resistant). Treat if HBV DNA elevated with ALT >2√ó ULN or fibrosis.</li>
      <li><strong>Hepatitis C:</strong> Direct-acting antivirals (DAAs) - specific regimen based on genotype and fibrosis. Common: Sofosbuvir/velpatasvir (Epclusa) 1 tab daily √ó12 weeks. Cure rate >95%.</li>
      <li><strong>Hepatitis D:</strong> Coinfection with HBV only; pegylated interferon-alpha is traditional therapy. Bulevirtide (Hepcludex) newly approved.</li>
      <li><strong>Hepatitis E:</strong> Usually self-limited; chronic in immunocompromised - reduce immunosuppression, consider ribavirin.</li>
      <li><strong>IMCRG Reference:</strong> <a href="im_guide.html#viral-hepatitis" style="color:#004080">#121 Acute Viral Hepatitis</a> - serologic workup, acute liver failure criteria</li>
    </ul>
  </div>
</section>

<!-- TICKBORNE -->
<section id="tickborne-infections">
  <h2>Tickborne Infections</h2>

  <button class="collapsible">Lyme disease ‚Äî Borrelia burgdorferi</button>
  <div class="panel">
    <ul>
      <li>Early localized (erythema migrans): Doxycycline 100 mg PO BID √ó10‚Äì21 d.</li>
      <li>Pregnancy/children <8: Amoxicillin 500 mg PO TID √ó14‚Äì21 d (weight/age adjust) or cefuroxime.</li>
      <li>Neurocardiac Lyme: Ceftriaxone 2 g IV q24h √ó14‚Äì28 d for neurologic or severe cardiac involvement.</li>
    </ul>
  </div>

  <button class="collapsible">Anaplasmosis / Ehrlichiosis</button>
  <div class="panel">
    <ul>
      <li>Empiric: Doxycycline 100 mg PO/IV twice daily √ó10‚Äì14 d; treat promptly on suspicion regardless of age.</li>
      <li>Presentation: fever, cytopenias, elevated LFTs; can be severe in immunocompromised.</li>
    </ul>
  </div>

  <button class="collapsible">Babesiosis</button>
  <div class="panel">
    <ul>
      <li>Mild‚Äìmoderate: Atovaquone 750 mg PO BID + Azithromycin 500 mg PO day1 then 250 mg PO daily √ó7‚Äì10 d.</li>
      <li>Severe: Clindamycin + Quinine IV; consider exchange transfusion for high parasitemia or severe hemolysis.</li>
    </ul>
  </div>

  <button class="collapsible">Rocky Mountain Spotted Fever</button>
  <div class="panel">
    <ul>
      <li>Empiric: Doxycycline 100 mg PO/IV BID for adults and children; treat immediately on suspicion.</li>
      <li>Duration typically 5‚Äì14 d depending on clinical course.</li>
    </ul>
  </div>
</section>

<!-- VIRAL ENCEPHALOPATHIES -->
<section id="viral-encephalopathies">
  <h2>Viral Encephalopathies / Arboviral Encephalitis</h2>

  <button class="collapsible">West Nile Virus (WNV)</button>
  <div class="panel">
    <ul>
      <li>Flavivirus transmitted by Culex mosquitoes; most infections asymptomatic or mild febrile illness.</li>
      <li>Neuroinvasive disease: meningitis, encephalitis, acute flaccid paralysis ‚Äî supportive care only (ICU as needed).</li>
      <li>Diagnosis: CSF/serum IgM, PCR early; consider neuroimaging and EEG for encephalopathy.</li>
    </ul>
  </div>

  <button class="collapsible">Eastern Equine Encephalitis (EEE)</button>
  <div class="panel">
    <ul>
      <li>Alphavirus with high mortality; supportive ICU care, aggressive management of seizures and intracranial pressure.</li>
      <li>No proven antiviral therapy; early recognition and supportive measures crucial.</li>
    </ul>
  </div>

  <button class="collapsible">St. Louis Encephalitis (SLE)</button>
  <div class="panel">
    <ul>
      <li>Flavivirus transmitted by mosquitoes; elderly at higher risk for severe neuroinvasive disease.</li>
      <li>Treatment supportive; involve neurology/ICU for severe cases.</li>
    </ul>
  </div>

  <button class="collapsible">Japanese Encephalitis (JEV)</button>
  <div class="panel">
    <ul>
      <li>Flavivirus endemic in Asia; severe encephalitis possible in a subset.</li>
      <li>Prevention: vaccine for travelers/residents in endemic areas; treatment supportive.</li>
    </ul>
  </div>

  <button class="collapsible">Rabies (neurologic phase)</button>
  <div class="panel">
    <ul>
      <li>Once symptomatic, rabies is almost universally fatal; immediate post-exposure prophylaxis (vaccine + RIG) is critical after exposures.</li>
      <li>If symptomatic, supportive ICU care; consult public health and infectious disease immediately.</li>
    </ul>
  </div>

  <button class="collapsible">HSV Encephalitis</button>
  <div class="panel">
    <ul>
      <li>HSV-1 is the most common cause of sporadic viral encephalitis in adults.</li>
      <li>Treatment: Acyclovir 10 mg/kg IV q8h (adjust renal) for 14‚Äì21 days; start immediately if suspected.</li>
    </ul>
  </div>
</section>

<!-- CALCULATORS -->
<section id="calculators">
  <h2>Calculators</h2>

  <div class="calculator" aria-labelledby="crcl-heading">
    <h3 id="crcl-heading">CrCl (Cockcroft-Gault)</h3>
    <div style="display:flex;gap:10px;flex-wrap:wrap;align-items:center">
      <label>Weight (kg): <input id="wt" type="number" style="width:110px"></label>
      <label>Age (yr): <input id="age" type="number" style="width:90px"></label>
      <label>Serum Cr (mg/dL): <input id="cr" type="number" step="0.01" style="width:110px"></label>
      <label>Female? <input id="female" type="checkbox" /></label>
      <button onclick="calcCrCl()" style="padding:6px 10px">Calculate</button>
    </div>
    <p id="crclResult" class="muted" style="margin-top:8px"></p>
  </div>

  <div class="calculator" aria-labelledby="sirs-heading">
    <h3 id="sirs-heading">SIRS / qSOFA Quick</h3>
    <div style="display:flex;gap:10px;flex-wrap:wrap;align-items:center">
      <label>Temp (¬∞C): <input id="temp" type="number" step="0.1" style="width:90px"></label>
      <label>HR: <input id="hr" type="number" style="width:80px"></label>
      <label>RR: <input id="rr" type="number" style="width:80px"></label>
      <label>MAP: <input id="map" type="number" style="width:90px"></label>
      <label>Mental: 
        <select id="mental">
          <option value="alert">alert</option>
          <option value="confused">confused</option>
          <option value="unresponsive">unresponsive</option>
        </select>
      </label>
      <button onclick="calcSIRS_qSOFA()" style="padding:6px 10px">Calculate</button>
    </div>
    <p id="sirsResult" class="muted" style="margin-top:8px"></p>
  </div>
</section>

<!-- RENAL DOSING -->
<section id="renal-dosing">
  <h2>Antibiotic Dosing in Renal Impairment</h2>
  <p class="muted">Adjust doses based on CrCl (Cockcroft-Gault). Always verify with pharmacy for critically ill patients.</p>

  <button class="collapsible">Beta-Lactams</button>
  <div class="panel">
    <table>
      <thead><tr><th>Drug</th><th>Normal Dose</th><th>CrCl 30-50</th><th>CrCl 10-30</th><th>CrCl <10 / HD</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Piperacillin-Tazobactam</strong></td><td>4.5g IV q6h</td><td>3.375g IV q6h</td><td>2.25g IV q6h</td><td>2.25g IV q8h (give after HD)</td><td>Extended infusion (4h) preferred for serious infections</td></tr>
        <tr><td><strong>Cefepime</strong></td><td>2g IV q8h</td><td>2g IV q12h</td><td>1-2g IV q24h</td><td>1g IV q24h (give after HD)</td><td>Neurotoxicity risk increases in renal impairment</td></tr>
        <tr><td><strong>Ceftriaxone</strong></td><td>1-2g IV q24h</td><td>No adjustment</td><td>No adjustment</td><td>No adjustment</td><td>Biliary excretion; rare agent that doesn't need renal adjustment</td></tr>
        <tr><td><strong>Ceftazidime</strong></td><td>2g IV q8h</td><td>2g IV q12h</td><td>1-2g IV q24h</td><td>1g IV q24h (give after HD)</td><td></td></tr>
        <tr><td><strong>Meropenem</strong></td><td>1g IV q8h</td><td>1g IV q12h</td><td>500mg IV q12h</td><td>500mg IV q24h (give after HD)</td><td>Preferred carbapenem in CNS infections</td></tr>
        <tr><td><strong>Ampicillin-Sulbactam</strong></td><td>3g IV q6h</td><td>3g IV q8h</td><td>3g IV q12h</td><td>3g IV q24h (give after HD)</td><td></td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Vancomycin</button>
  <div class="panel">
    <table>
      <thead><tr><th>CrCl (mL/min)</th><th>Loading Dose</th><th>Maintenance Dose</th><th>Monitoring</th></tr></thead>
      <tbody>
        <tr><td>>90</td><td>25-30 mg/kg √ó 1</td><td>15-20 mg/kg IV q8-12h</td><td>AUC-guided dosing preferred; target AUC/MIC 400-600</td></tr>
        <tr><td>50-90</td><td>25-30 mg/kg √ó 1</td><td>15-20 mg/kg IV q12h</td><td>Trough-based: target 15-20 mcg/mL for serious infections</td></tr>
        <tr><td>30-50</td><td>25-30 mg/kg √ó 1</td><td>15-20 mg/kg IV q24h</td><td>Consider pharmacy consult</td></tr>
        <tr><td>10-30</td><td>25-30 mg/kg √ó 1</td><td>15-20 mg/kg IV q24-48h</td><td>Check level before 3rd dose</td></tr>
        <tr><td><10 / HD</td><td>25-30 mg/kg √ó 1</td><td>Re-dose when level <15-20</td><td>Give after HD; HD removes ~30-40%</td></tr>
        <tr><td>CRRT</td><td>25-30 mg/kg √ó 1</td><td>10-15 mg/kg q24h</td><td>Highly variable; frequent level monitoring</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Key Points:</strong> Always give loading dose regardless of renal function. AUC-guided dosing is now preferred over trough-based monitoring per 2020 IDSA/ASHP guidelines.</p>
  </div>

  <button class="collapsible">Aminoglycosides</button>
  <div class="panel">
    <table>
      <thead><tr><th>Drug</th><th>Normal Dose (Extended Interval)</th><th>CrCl 40-59</th><th>CrCl 20-39</th><th>CrCl <20</th><th>HD</th></tr></thead>
      <tbody>
        <tr><td><strong>Gentamicin / Tobramycin</strong></td><td>5-7 mg/kg IV q24h</td><td>5-7 mg/kg q36h</td><td>5-7 mg/kg q48h</td><td>Re-dose based on levels</td><td>2 mg/kg post-HD</td></tr>
        <tr><td><strong>Amikacin</strong></td><td>15-20 mg/kg IV q24h</td><td>15-20 mg/kg q36h</td><td>15-20 mg/kg q48h</td><td>Re-dose based on levels</td><td>7.5 mg/kg post-HD</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Key Points:</strong> Extended-interval (once-daily) dosing preferred. Check random level at 6-14h post-dose for Hartford nomogram. Avoid in CrCl <20 if possible. Nephrotoxicity and ototoxicity risks increase with renal impairment.</p>
  </div>

  <button class="collapsible">Fluoroquinolones</button>
  <div class="panel">
    <table>
      <thead><tr><th>Drug</th><th>Normal Dose</th><th>CrCl 20-49</th><th>CrCl <20 / HD</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Levofloxacin</strong></td><td>750mg PO/IV q24h</td><td>750mg q48h</td><td>500mg q48h (give after HD)</td><td>Excellent oral bioavailability</td></tr>
        <tr><td><strong>Ciprofloxacin</strong></td><td>400mg IV q8-12h / 500-750mg PO q12h</td><td>400mg IV q12h / 500mg PO q12h</td><td>400mg IV q24h / 500mg PO q24h</td><td>Oral absorption affected by divalent cations</td></tr>
        <tr><td><strong>Moxifloxacin</strong></td><td>400mg PO/IV q24h</td><td>No adjustment</td><td>No adjustment</td><td>Hepatic metabolism; no renal adjustment needed</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Other Common Antibiotics</button>
  <div class="panel">
    <table>
      <thead><tr><th>Drug</th><th>Normal Dose</th><th>CrCl 30-50</th><th>CrCl 10-30</th><th>CrCl <10 / HD</th></tr></thead>
      <tbody>
        <tr><td><strong>TMP-SMX (Bactrim)</strong></td><td>5-20 mg/kg/day TMP divided q6-12h</td><td>50-100% dose</td><td>50% dose q12-24h</td><td>Avoid if possible; if required, 50% dose q24h after HD</td></tr>
        <tr><td><strong>Metronidazole</strong></td><td>500mg IV/PO q8h</td><td>No adjustment</td><td>No adjustment</td><td>No adjustment (but give after HD to avoid removal)</td></tr>
        <tr><td><strong>Azithromycin</strong></td><td>500mg IV/PO q24h</td><td>No adjustment</td><td>No adjustment</td><td>No adjustment</td></tr>
        <tr><td><strong>Doxycycline</strong></td><td>100mg PO/IV q12h</td><td>No adjustment</td><td>No adjustment</td><td>No adjustment</td></tr>
        <tr><td><strong>Linezolid</strong></td><td>600mg IV/PO q12h</td><td>No adjustment</td><td>No adjustment</td><td>No adjustment (metabolites accumulate; use with caution >2wk)</td></tr>
        <tr><td><strong>Daptomycin</strong></td><td>6-10 mg/kg IV q24h</td><td>No adjustment</td><td>6-10 mg/kg IV q48h</td><td>6-10 mg/kg IV q48h (give after HD)</td></tr>
        <tr><td><strong>Fluconazole</strong></td><td>Loading then 400mg IV/PO q24h</td><td>50% dose</td><td>50% dose</td><td>50% dose (give after HD)</td></tr>
      </tbody>
    </table>
  </div>
</section>

<!-- IV TO PO CONVERSION -->
<section id="iv-to-po">
  <h2>IV to PO Conversion Guide</h2>
  <p class="muted">Transition to oral therapy when patient is hemodynamically stable, afebrile, tolerating PO, and GI tract functional.</p>

  <button class="collapsible">Excellent Oral Bioavailability (>90%) ‚Äî Prefer PO</button>
  <div class="panel">
    <table>
      <thead><tr><th>Drug</th><th>Oral Bioavailability</th><th>IV Dose ‚Üí PO Dose</th><th>Key Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Fluoroquinolones</strong></td><td>~95-100%</td><td>IV = PO (1:1)</td><td>Avoid with divalent cations (Ca, Mg, Fe, antacids). Levofloxacin 750mg IV = 750mg PO</td></tr>
        <tr><td><strong>Linezolid</strong></td><td>~100%</td><td>IV = PO (1:1)</td><td>600mg IV = 600mg PO. Can switch immediately.</td></tr>
        <tr><td><strong>Metronidazole</strong></td><td>~100%</td><td>IV = PO (1:1)</td><td>500mg IV = 500mg PO. Excellent absorption.</td></tr>
        <tr><td><strong>TMP-SMX</strong></td><td>~95%</td><td>IV = PO (1:1)</td><td>DS (160/800mg) = standard oral dose</td></tr>
        <tr><td><strong>Fluconazole</strong></td><td>~90%</td><td>IV = PO (1:1)</td><td>Can switch day 1 if tolerating PO</td></tr>
        <tr><td><strong>Doxycycline</strong></td><td>~95%</td><td>IV = PO (1:1)</td><td>100mg IV = 100mg PO. Take with food to reduce GI upset.</td></tr>
        <tr><td><strong>Clindamycin</strong></td><td>~90%</td><td>IV = PO (1:1)</td><td>600mg IV q8h = 450mg PO q6h (adjust for frequency)</td></tr>
        <tr><td><strong>Voriconazole</strong></td><td>~96%</td><td>IV = PO (1:1)</td><td>Loading then maintenance. Take 1h before or 1h after meals.</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Clinical Pearl:</strong> For drugs with excellent bioavailability, there is NO benefit to continuing IV when PO is tolerated. Switch early to reduce line days, cost, and infection risk.</p>
  </div>

  <button class="collapsible">Good Oral Bioavailability (50-80%) ‚Äî PO Often Acceptable</button>
  <div class="panel">
    <table>
      <thead><tr><th>Drug</th><th>Oral Bioavailability</th><th>Conversion</th><th>Key Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Amoxicillin-Clavulanate</strong></td><td>~75-90%</td><td>Use PO for step-down</td><td>875/125mg PO BID is standard</td></tr>
        <tr><td><strong>Cephalexin</strong></td><td>~90%</td><td>Use for PO step-down from cefazolin</td><td>500mg PO QID or 1g PO TID</td></tr>
        <tr><td><strong>Ciprofloxacin</strong></td><td>~70-80%</td><td>400mg IV q12h = 500mg PO q12h</td><td>Absorption reduced by dairy, antacids</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Poor Oral Bioavailability ‚Äî IV Required</button>
  <div class="panel">
    <table>
      <thead><tr><th>Drug</th><th>Oral Bioavailability</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Vancomycin (IV)</strong></td><td>~0% systemic</td><td>Oral vancomycin is for C. diff only (stays in GI tract). No PO equivalent for systemic infections.</td></tr>
        <tr><td><strong>Aminoglycosides</strong></td><td>~0% systemic</td><td>No oral option. Must complete IV course.</td></tr>
        <tr><td><strong>Amphotericin B</strong></td><td>~0% systemic</td><td>No oral option for systemic infections.</td></tr>
        <tr><td><strong>Beta-lactams (most)</strong></td><td>Variable, often <50%</td><td>Piperacillin-tazobactam, cefepime, meropenem have no PO equivalents. Step down to different oral agent.</td></tr>
        <tr><td><strong>Daptomycin</strong></td><td>~0%</td><td>IV only. No oral option.</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Step-Down Strategy for IV-Only Drugs:</strong> Transition to a different antibiotic class with PO option. Example: Pip-tazo ‚Üí amoxicillin-clavulanate; Cefepime ‚Üí levofloxacin; Vancomycin ‚Üí linezolid (if appropriate).</p>
  </div>
</section>

<!-- DURATION OF THERAPY -->
<section id="duration-therapy">
  <h2>Duration of Therapy Summary</h2>
  <p class="muted">Evidence-based duration recommendations. Shorter courses often equivalent; longer courses increase resistance risk.</p>

  <button class="collapsible">Respiratory Infections</button>
  <div class="panel">
    <table>
      <thead><tr><th>Infection</th><th>Duration</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Community-Acquired Pneumonia</strong></td><td>5 days (minimum)</td><td>Stop when afebrile ‚â•48h and clinically stable. Longer not better.</td></tr>
        <tr><td><strong>Hospital-Acquired / VAP</strong></td><td>7 days</td><td>Per 2016 IDSA guidelines. Longer for Pseudomonas or slow response.</td></tr>
        <tr><td><strong>Aspiration Pneumonia</strong></td><td>5-7 days</td><td>Same as CAP if no abscess/empyema.</td></tr>
        <tr><td><strong>Lung Abscess</strong></td><td>4-6 weeks (minimum)</td><td>Until imaging shows resolution or significant improvement.</td></tr>
        <tr><td><strong>Empyema</strong></td><td>2-4 weeks</td><td>With drainage. Duration based on clinical response.</td></tr>
        <tr><td><strong>COPD Exacerbation (if antibiotics indicated)</strong></td><td>5 days</td><td>Azithromycin √ó 3d or doxycycline √ó 5d typically used.</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Urinary Tract Infections</button>
  <div class="panel">
    <table>
      <thead><tr><th>Infection</th><th>Duration</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Uncomplicated Cystitis (women)</strong></td><td>3-5 days</td><td>Nitrofurantoin 5d, TMP-SMX 3d, fosfomycin √ó1 dose</td></tr>
        <tr><td><strong>Uncomplicated Pyelonephritis</strong></td><td>5-7 days</td><td>FQ 5-7d; TMP-SMX 14d; beta-lactams 10-14d</td></tr>
        <tr><td><strong>Complicated UTI / Pyelonephritis</strong></td><td>7-14 days</td><td>Depends on clinical response, source control</td></tr>
        <tr><td><strong>Catheter-Associated UTI</strong></td><td>7 days</td><td>Remove/replace catheter. 5 days may be adequate for rapid response.</td></tr>
        <tr><td><strong>UTI in Men</strong></td><td>7-14 days</td><td>All UTIs in men are considered complicated.</td></tr>
        <tr><td><strong>Prostatitis (acute bacterial)</strong></td><td>2-4 weeks</td><td>FQ preferred for prostatic penetration.</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Skin & Soft Tissue Infections</button>
  <div class="panel">
    <table>
      <thead><tr><th>Infection</th><th>Duration</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Uncomplicated Cellulitis</strong></td><td>5 days</td><td>Extend to 10-14d if slow response. Elevation, compression important.</td></tr>
        <tr><td><strong>Purulent SSTI (Abscess)</strong></td><td>5-7 days (post-I&D)</td><td>Small abscesses with adequate drainage may not need antibiotics.</td></tr>
        <tr><td><strong>Necrotizing Fasciitis</strong></td><td>Until debridements complete + stable</td><td>Duration based on source control; typically 2-4 weeks total.</td></tr>
        <tr><td><strong>Diabetic Foot Infection (soft tissue only)</strong></td><td>1-2 weeks</td><td>Longer if osteomyelitis present.</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Bloodstream Infections</button>
  <div class="panel">
    <table>
      <thead><tr><th>Organism / Situation</th><th>Duration</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Uncomplicated Gram-negative bacteremia</strong></td><td>7 days</td><td>From day of first negative blood culture or clinical improvement.</td></tr>
        <tr><td><strong>S. aureus bacteremia (uncomplicated)</strong></td><td>14 days (minimum)</td><td>"Uncomplicated" = removable focus, no endocarditis on TEE, negative repeat cultures ‚â§4 days, no metastatic infection, no prosthetic material.</td></tr>
        <tr><td><strong>S. aureus bacteremia (complicated)</strong></td><td>4-6 weeks</td><td>ID consult strongly recommended. TEE required.</td></tr>
        <tr><td><strong>Candida fungemia</strong></td><td>14 days (minimum)</td><td>From first negative blood culture. Remove all lines. Ophtho exam for endophthalmitis.</td></tr>
        <tr><td><strong>Coag-negative Staph (if true pathogen)</strong></td><td>5-7 days</td><td>Remove line. Often contaminant ‚Äî see Blood Culture Interpretation section.</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Bone & Joint / Endocarditis</button>
  <div class="panel">
    <table>
      <thead><tr><th>Infection</th><th>Duration</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Septic Arthritis (native joint)</strong></td><td>2-4 weeks</td><td>Drainage essential. Duration based on organism and response.</td></tr>
        <tr><td><strong>Osteomyelitis (no hardware)</strong></td><td>4-6 weeks</td><td>IV vs. PO: OVIVA trial showed oral non-inferior if good bioavailability agent used.</td></tr>
        <tr><td><strong>Osteomyelitis (with hardware)</strong></td><td>6 weeks ‚Üí chronic suppression</td><td>If hardware retained, may need indefinite suppression.</td></tr>
        <tr><td><strong>Native Valve Endocarditis (Strep)</strong></td><td>4 weeks</td><td>2 weeks possible with gentamicin synergy for highly susceptible strains.</td></tr>
        <tr><td><strong>Native Valve Endocarditis (Staph)</strong></td><td>6 weeks</td><td>ID and cardiology involvement essential.</td></tr>
        <tr><td><strong>Prosthetic Valve Endocarditis</strong></td><td>‚â•6 weeks</td><td>Usually requires surgical intervention. Complex management.</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Intra-Abdominal & GI</button>
  <div class="panel">
    <table>
      <thead><tr><th>Infection</th><th>Duration</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Uncomplicated Intra-Abdominal Infection</strong></td><td>4 days (max)</td><td>STOP-IT trial: 4d vs. 8d equivalent if adequate source control.</td></tr>
        <tr><td><strong>Complicated Intra-Abdominal Infection</strong></td><td>4-7 days</td><td>After source control. Longer only if inadequate source control.</td></tr>
        <tr><td><strong>C. difficile (initial, non-severe)</strong></td><td>10 days</td><td>Fidaxomicin or oral vancomycin.</td></tr>
        <tr><td><strong>C. difficile (fulminant)</strong></td><td>10 days minimum</td><td>Oral vancomycin + IV metronidazole. Surgical consult if toxic megacolon.</td></tr>
        <tr><td><strong>Cholangitis (post-biliary drainage)</strong></td><td>4-7 days</td><td>Shorter if source control adequate and rapid defervescence.</td></tr>
        <tr><td><strong>Spontaneous Bacterial Peritonitis</strong></td><td>5 days</td><td>Repeat paracentesis not required if clinical improvement.</td></tr>
      </tbody>
    </table>
  </div>
</section>

<!-- PENICILLIN ALLERGY -->
<section id="penicillin-allergy">
  <h2>Penicillin Allergy Evaluation</h2>
  <p class="muted">~90% of reported penicillin allergies are NOT true IgE-mediated allergies. Evaluation enables optimal antibiotic selection.</p>

  <button class="collapsible">Classifying Penicillin Allergy</button>
  <div class="panel">
    <table>
      <thead><tr><th>Type</th><th>Characteristics</th><th>Examples</th><th>Risk Level</th></tr></thead>
      <tbody>
        <tr><td><strong>Type I (IgE-mediated)</strong></td><td>Immediate (<1-6 hours), urticaria, angioedema, anaphylaxis, bronchospasm</td><td>"Throat swelling", "couldn't breathe", "hives all over", "needed epinephrine"</td><td>HIGH ‚Äî avoid unless skin testing negative</td></tr>
        <tr><td><strong>Severe non-IgE</strong></td><td>SJS/TEN, DRESS, serum sickness, hemolytic anemia, interstitial nephritis</td><td>Blistering rash, fever + rash + organ involvement, onset days-weeks</td><td>HIGH ‚Äî avoid penicillins AND cephalosporins</td></tr>
        <tr><td><strong>Benign/Low-risk</strong></td><td>Delayed, mild rash, GI upset, "unknown", childhood reaction not remembered</td><td>"Rash as a kid", "stomach upset", "not sure what happened"</td><td>LOW ‚Äî likely can use cephalosporins, possibly penicillins</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Cephalosporin Cross-Reactivity (THE REAL DATA)</button>
  <div class="panel">
    <p><strong>Historical teaching of 10% cross-reactivity is WRONG.</strong></p>
    <p>Actual cross-reactivity rates based on R1 side chain similarity:</p>
    <table>
      <thead><tr><th>Scenario</th><th>Cross-Reactivity</th><th>Clinical Implication</th></tr></thead>
      <tbody>
        <tr><td>Overall cephalosporin cross-reactivity with penicillin allergy</td><td><strong>~1-2%</strong></td><td>Low risk. Most patients with "penicillin allergy" can receive cephalosporins.</td></tr>
        <tr><td><strong>Aminopenicillins ‚Üí 1st/2nd gen cephalosporins</strong> (similar R1 side chain)</td><td>~10-15%</td><td>Amoxicillin/ampicillin share side chain with cefadroxil, cephalexin, cefaclor. Avoid these specific agents.</td></tr>
        <tr><td><strong>Any penicillin ‚Üí 3rd/4th gen cephalosporins</strong></td><td><strong><1%</strong></td><td>Ceftriaxone, cefepime, ceftazidime have distinct R1 side chains. SAFE in most penicillin-allergic patients.</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Bottom Line:</strong> Ceftriaxone and cefepime can be safely given to most patients with penicillin allergy (except anaphylaxis or severe reactions). 1st/2nd gen cephalosporins have higher cross-reactivity with aminopenicillins specifically.</p>
  </div>

  <button class="collapsible">Decision Algorithm</button>
  <div class="panel">
    <h4>Step 1: Characterize the Reaction</h4>
    <ul>
      <li>What happened? (specific symptoms)</li>
      <li>How soon after taking the drug? (minutes vs. days)</li>
      <li>Did they need treatment? (epinephrine, hospitalization)</li>
      <li>How long ago? (>10 years, IgE wanes)</li>
      <li>Have they tolerated penicillins or cephalosporins since?</li>
    </ul>
    
    <h4>Step 2: Risk Stratify</h4>
    <table>
      <thead><tr><th>Risk Category</th><th>History</th><th>Recommendation</th></tr></thead>
      <tbody>
        <tr><td><strong>Low Risk</strong></td><td>Unknown reaction, GI upset, non-urticarial rash, reaction >10 years ago, tolerated cephalosporins since</td><td>Give cephalosporins (any generation) without testing. Consider penicillin challenge if needed.</td></tr>
        <tr><td><strong>Moderate Risk</strong></td><td>Urticaria or pruritic rash within 6 hours, isolated angioedema</td><td>Give 3rd/4th gen cephalosporins (ceftriaxone, cefepime). Consider penicillin skin testing if penicillin strongly preferred.</td></tr>
        <tr><td><strong>High Risk</strong></td><td>Anaphylaxis, bronchospasm, hypotension, required epinephrine</td><td>Avoid penicillins and consider avoiding cephalosporins. Penicillin skin testing before use. Use alternative class.</td></tr>
        <tr><td><strong>Contraindicated</strong></td><td>SJS/TEN, DRESS, hemolytic anemia, interstitial nephritis</td><td>NEVER rechallenge with penicillins or cephalosporins. Absolute contraindication.</td></tr>
      </tbody>
    </table>
    
    <h4>Step 3: Alternatives When Avoiding Beta-Lactams</h4>
    <ul>
      <li><strong>Gram-positive coverage:</strong> Vancomycin, daptomycin, linezolid</li>
      <li><strong>Gram-negative coverage:</strong> Fluoroquinolones, aminoglycosides, aztreonam (NO cross-reactivity with penicillins)</li>
      <li><strong>Anaerobic coverage:</strong> Metronidazole, clindamycin</li>
    </ul>
  </div>

  <button class="collapsible">Penicillin Skin Testing & Desensitization</button>
  <div class="panel">
    <h4>Penicillin Skin Testing</h4>
    <ul>
      <li><strong>Indication:</strong> High-risk allergy history when penicillin is strongly preferred (e.g., syphilis in pregnancy, enterococcal endocarditis)</li>
      <li><strong>NPV:</strong> >95% ‚Äî negative test means <1% chance of IgE-mediated reaction</li>
      <li><strong>Process:</strong> Prick test followed by intradermal testing with penicillin G, penicilloyl-polylysine (Pre-Pen), and minor determinant mixture</li>
      <li><strong>If negative:</strong> Can give penicillins safely (consider supervised first dose)</li>
    </ul>
    
    <h4>Desensitization</h4>
    <ul>
      <li><strong>Indication:</strong> TRUE IgE-mediated allergy AND no alternative antibiotic acceptable</li>
      <li><strong>Process:</strong> Incremental doses given over 4-12 hours in monitored setting (ICU or allergy clinic)</li>
      <li><strong>Duration:</strong> Desensitization is temporary ‚Äî must maintain continuous drug exposure. If stopped >24-48h, must repeat desensitization.</li>
      <li><strong>Contraindicated:</strong> SJS/TEN, DRESS, other severe non-IgE reactions</li>
    </ul>
  </div>
</section>

<!-- BLOOD CULTURE INTERPRETATION -->
<section id="blood-culture-interpretation">
  <h2>Blood Culture Interpretation</h2>
  <p class="muted">Distinguishing true pathogens from contaminants is critical for appropriate antibiotic use.</p>

  <button class="collapsible">Always Pathogens (Treat if Isolated)</button>
  <div class="panel">
    <table>
      <thead><tr><th>Organism</th><th>Clinical Significance</th><th>Key Actions</th></tr></thead>
      <tbody>
        <tr><td><strong>Staphylococcus aureus</strong></td><td>ALWAYS significant ‚Äî even 1 positive bottle</td><td>Repeat cultures, TEE (within 5-7 days), evaluate for metastatic infection, ID consult recommended. Minimum 14 days IV therapy.</td></tr>
        <tr><td><strong>Streptococcus pneumoniae</strong></td><td>Always significant</td><td>Source: usually pneumonia, meningitis, or spontaneous. Look for immunocompromise if recurrent.</td></tr>
        <tr><td><strong>Streptococcus pyogenes (GAS)</strong></td><td>Always significant</td><td>Source: skin/soft tissue, pharyngitis, necrotizing fasciitis. Aggressive infection ‚Äî evaluate for deep source.</td></tr>
        <tr><td><strong>Streptococcus agalactiae (GBS)</strong></td><td>Always significant</td><td>Common in diabetics, elderly, pregnancy. Look for skin, UTI, or endovascular source.</td></tr>
        <tr><td><strong>Enterobacteriaceae</strong> (E. coli, Klebsiella, etc.)</td><td>Always significant</td><td>Source: UTI, biliary, intra-abdominal, line infection. Repeat cultures to document clearance.</td></tr>
        <tr><td><strong>Pseudomonas aeruginosa</strong></td><td>Always significant</td><td>Often healthcare-associated. Look for pneumonia, UTI, line infection, neutropenia.</td></tr>
        <tr><td><strong>Candida species</strong></td><td>ALWAYS significant ‚Äî even 1 positive bottle</td><td>Remove all lines, repeat cultures until negative, ophtho exam, echocardiogram if risk factors. ID consult. Minimum 14 days from first negative culture.</td></tr>
        <tr><td><strong>Neisseria meningitidis</strong></td><td>Always significant</td><td>Meningitis, meningococcemia. Droplet precautions. Prophylaxis for close contacts.</td></tr>
        <tr><td><strong>Listeria monocytogenes</strong></td><td>Always significant</td><td>Meningitis, bacteremia in immunocompromised, elderly, pregnancy. Requires ampicillin (not cephalosporins).</td></tr>
      </tbody>
    </table>
  </div>

  <button class="collapsible">Common Contaminants (Evaluate Before Treating)</button>
  <div class="panel">
    <table>
      <thead><tr><th>Organism</th><th>Contaminant Probability</th><th>When to Consider True Pathogen</th></tr></thead>
      <tbody>
        <tr><td><strong>Coagulase-negative Staphylococci</strong> (S. epidermidis, etc.)</td><td>~70-80% are contaminants</td><td>True pathogen if: ‚â•2 bottles positive with same species, prosthetic device/hardware, central line, immunocompromised. Single positive bottle usually contaminant.</td></tr>
        <tr><td><strong>Corynebacterium (Diphtheroids)</strong></td><td>Usually contaminant</td><td>True pathogen if: prosthetic valve, hardware, immunocompromised, multiple positive bottles</td></tr>
        <tr><td><strong>Cutibacterium acnes</strong> (formerly Propionibacterium)</td><td>Usually contaminant</td><td>True pathogen if: shoulder hardware, CNS shunt, prosthetic joint. Takes 5-14 days to grow.</td></tr>
        <tr><td><strong>Bacillus species (not B. anthracis)</strong></td><td>Usually contaminant</td><td>True pathogen if: IV drug use, central line, immunocompromised, multiple positive bottles</td></tr>
        <tr><td><strong>Viridans group Streptococci</strong></td><td>Sometimes contaminant</td><td>True pathogen if: endocarditis risk factors, multiple positive bottles, neutropenia. Single bottle in healthy patient may be contaminant.</td></tr>
        <tr><td><strong>Micrococcus</strong></td><td>Almost always contaminant</td><td>Rarely pathogenic. Repeat cultures if clinically concerned.</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Key Principle:</strong> For likely contaminants, repeat blood cultures before starting antibiotics (unless critically ill). Two positive bottles with same organism = more likely true pathogen.</p>
  </div>

  <button class="collapsible">Interpreting Positive Bottles: 1 vs. 2</button>
  <div class="panel">
    <h4>Why 2 Sets (4 Bottles) Are Recommended</h4>
    <ul>
      <li>Single positive bottle more likely to represent contamination</li>
      <li>Sensitivity for detecting bacteremia increases with volume cultured</li>
      <li>Two positive bottles with same organism = high specificity for true bacteremia</li>
    </ul>
    
    <h4>Decision Framework</h4>
    <table>
      <thead><tr><th>Scenario</th><th>Interpretation</th><th>Action</th></tr></thead>
      <tbody>
        <tr><td>1/4 bottles positive with <strong>S. aureus</strong> or <strong>Candida</strong></td><td>TRUE PATHOGEN</td><td>Full workup and treatment. These are never contaminants.</td></tr>
        <tr><td>1/4 bottles positive with coag-neg Staph</td><td>Likely contaminant (~80%)</td><td>Repeat cultures. If repeat negative and low-risk patient, observe. If prosthetic device, treat as pathogen.</td></tr>
        <tr><td>2/4 bottles positive with coag-neg Staph (same species)</td><td>More likely pathogen (~50-70%)</td><td>Evaluate for line infection, hardware. Consider treatment, especially if clinical signs of infection.</td></tr>
        <tr><td>1/4 bottles positive with Gram-negative rod</td><td>Usually pathogen</td><td>Repeat cultures, evaluate source, treat. GNRs are rarely contaminants.</td></tr>
        <tr><td>Polymicrobial bacteremia</td><td>Consider GI source</td><td>Evaluate for intra-abdominal abscess, perforation, biliary infection. May need imaging.</td></tr>
      </tbody>
    </table>
    
    <h4>Time to Positivity</h4>
    <p><strong>Clinical Pearl:</strong> Faster time to positivity generally correlates with higher bacterial burden and more severe infection. Cultures positive in <12 hours suggest high-grade bacteremia.</p>
  </div>

  <button class="collapsible">Special Situations</button>
  <div class="panel">
    <h4>Culture-Negative Endocarditis Organisms (HACEK and Beyond)</h4>
    <ul>
      <li><strong>HACEK organisms:</strong> Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella ‚Äî slow-growing, cause culture-negative endocarditis</li>
      <li><strong>Coxiella burnetii (Q fever):</strong> Requires serology</li>
      <li><strong>Bartonella:</strong> Serology and PCR; associated with cat exposure, homelessness</li>
      <li><strong>Tropheryma whipplei:</strong> Whipple disease; PCR for diagnosis</li>
      <li><strong>Brucella:</strong> Prolonged incubation needed; notify lab if suspected</li>
    </ul>
    
    <h4>When to Suspect Anaerobic Bacteremia</h4>
    <ul>
      <li>Intra-abdominal source (especially with polymicrobial cultures)</li>
      <li>Female genital tract infections</li>
      <li>Aspiration pneumonia with abscess</li>
      <li>Decubitus ulcers or diabetic foot infections</li>
      <li><strong>Common anaerobes:</strong> Bacteroides fragilis, Clostridium species, Fusobacterium</li>
    </ul>
    
    <h4>Persistent Bacteremia ‚Äî Red Flag</h4>
    <p>If cultures remain positive >48-72 hours despite appropriate antibiotics:</p>
    <ul>
      <li>Endocarditis (get TEE)</li>
      <li>Undrained abscess (get imaging)</li>
      <li>Infected hardware/device (may need removal)</li>
      <li>Wrong antibiotic (check susceptibilities)</li>
      <li>Septic thrombophlebitis (consider anticoagulation)</li>
    </ul>
  </div>
</section>

<!-- OPPORTUNISTIC INFECTIONS -->
<section id="opportunistic-infections">
  <h2>Opportunistic Infections in Immunocompromised Hosts</h2>
  <p class="muted">HIV/AIDS, transplant recipients, and immunosuppressed patients. CD4 count guides prophylaxis and differential. Cross-reference: <a href="im_guide.html#hiv" style="color: #0366d6;">üìö IMCRG: HIV/AIDS</a></p>

  <button class="collapsible">Pneumocystis jirovecii Pneumonia (PCP)</button>
  <div class="panel">
    <h4>Risk Groups</h4>
    <ul>
      <li><strong>HIV:</strong> CD4 <200 cells/ŒºL (most common)</li>
      <li><strong>Transplant:</strong> Especially first 6-12 months post-transplant</li>
      <li><strong>Hematologic malignancy:</strong> Particularly with prolonged lymphopenia</li>
      <li><strong>High-dose corticosteroids:</strong> ‚â•20 mg prednisone equivalent for ‚â•4 weeks</li>
    </ul>
    <h4>Clinical Features</h4>
    <ul>
      <li>Subacute dyspnea, dry cough, fever over days to weeks (HIV) vs. more acute (non-HIV)</li>
      <li>Hypoxia out of proportion to exam findings</li>
      <li>Bilateral interstitial infiltrates, "ground glass" on CT</li>
      <li>Elevated LDH (nonspecific but supportive)</li>
      <li>Elevated beta-D-glucan (very sensitive)</li>
    </ul>
    <h4>Diagnosis</h4>
    <ul>
      <li><strong>Induced sputum:</strong> Sensitivity ~50-90% with immunofluorescent staining</li>
      <li><strong>BAL:</strong> Sensitivity >95%; gold standard if sputum negative</li>
      <li><strong>Beta-D-glucan:</strong> Highly sensitive; negative BDG essentially rules out PCP</li>
      <li><strong>PCR:</strong> Very sensitive but may detect colonization; use with clinical context</li>
    </ul>
    <h4>Treatment</h4>
    <table>
      <thead><tr><th>Severity</th><th>Treatment</th><th>Duration</th></tr></thead>
      <tbody>
        <tr><td><strong>Mild-Moderate</strong> (PaO2 >70, A-a gradient <35)</td><td>TMP-SMX 15-20 mg/kg/day (TMP component) PO divided TID</td><td>21 days (HIV), 14 days (non-HIV)</td></tr>
        <tr><td><strong>Severe</strong> (PaO2 ‚â§70 or A-a gradient ‚â•35)</td><td>TMP-SMX 15-20 mg/kg/day IV divided q6-8h + Prednisone 40mg BID √ó 5d, then 40mg daily √ó 5d, then 20mg daily √ó 11d</td><td>21 days (HIV)</td></tr>
      </tbody>
    </table>
    <h4>Alternative Regimens (Sulfa Allergy)</h4>
    <ul>
      <li><strong>Primaquine + Clindamycin:</strong> Primaquine 30mg PO daily + Clindamycin 600mg IV/PO q8h (check G6PD first)</li>
      <li><strong>Atovaquone:</strong> 750mg PO BID with food (mild disease only)</li>
      <li><strong>Pentamidine IV:</strong> 4 mg/kg IV daily (significant toxicity)</li>
    </ul>
    <h4>Adjunctive Steroids</h4>
    <ul>
      <li><strong>Indication:</strong> PaO2 <70 mmHg on room air or A-a gradient ‚â•35</li>
      <li><strong>Benefit:</strong> Reduces mortality in moderate-severe PCP (HIV patients)</li>
      <li><strong>Start within 72 hours</strong> of PCP treatment</li>
    </ul>
    <h4>Prophylaxis</h4>
    <table>
      <thead><tr><th>Regimen</th><th>Dose</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>TMP-SMX (first-line)</strong></td><td>1 DS tablet daily OR 1 SS tablet daily</td><td>Also covers Toxoplasma, some bacterial infections</td></tr>
        <tr><td><strong>Dapsone</strong></td><td>100mg PO daily</td><td>Check G6PD first</td></tr>
        <tr><td><strong>Atovaquone</strong></td><td>1500mg PO daily</td><td>Take with food; expensive</td></tr>
        <tr><td><strong>Pentamidine (inhaled)</strong></td><td>300mg via nebulizer monthly</td><td>Does not prevent extrapulmonary disease or Toxoplasma</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>When to Start/Stop Prophylaxis (HIV):</strong> Start when CD4 <200; stop when CD4 >200 for ‚â•3 months on ART.</p>
  </div>

  <button class="collapsible">Cytomegalovirus (CMV)</button>
  <div class="panel">
    <h4>Risk Groups</h4>
    <ul>
      <li><strong>Solid organ transplant:</strong> Highest risk with D+/R- (donor positive, recipient negative)</li>
      <li><strong>HSCT:</strong> Especially allogeneic, with GVHD</li>
      <li><strong>HIV:</strong> CD4 <50 cells/ŒºL</li>
    </ul>
    <h4>Clinical Syndromes</h4>
    <table>
      <thead><tr><th>Syndrome</th><th>Features</th><th>Diagnosis</th></tr></thead>
      <tbody>
        <tr><td><strong>CMV Syndrome</strong></td><td>Fever, malaise, leukopenia, thrombocytopenia, elevated LFTs</td><td>CMV viremia (PCR)</td></tr>
        <tr><td><strong>CMV Colitis</strong></td><td>Diarrhea (often bloody), abdominal pain, fever</td><td>Colonoscopy with biopsy showing CMV inclusions ("owl's eye"); tissue PCR</td></tr>
        <tr><td><strong>CMV Retinitis</strong></td><td>"Pizza pie" retinitis ‚Äî hemorrhages with white/yellow exudates; floaters, vision loss</td><td>Fundoscopic exam by ophthalmology</td></tr>
        <tr><td><strong>CMV Pneumonitis</strong></td><td>Interstitial pneumonia; common in HSCT</td><td>BAL with CMV PCR or culture + compatible clinical picture</td></tr>
        <tr><td><strong>CMV Esophagitis</strong></td><td>Odynophagia, large shallow ulcers (vs. multiple small ulcers in HSV)</td><td>EGD with biopsy</td></tr>
      </tbody>
    </table>
    <h4>Treatment</h4>
    <table>
      <thead><tr><th>Setting</th><th>First-Line</th><th>Duration</th></tr></thead>
      <tbody>
        <tr><td><strong>CMV Disease (induction)</strong></td><td>Ganciclovir 5 mg/kg IV q12h OR Valganciclovir 900mg PO BID</td><td>14-21 days until viremia cleared</td></tr>
        <tr><td><strong>CMV Retinitis (induction)</strong></td><td>Ganciclovir 5 mg/kg IV q12h √ó 14-21 days, then maintenance</td><td>Until immune reconstitution (CD4 >100 √ó 6mo)</td></tr>
        <tr><td><strong>Maintenance (retinitis)</strong></td><td>Valganciclovir 900mg PO daily</td><td>Continue until CD4 >100 for 3-6 months</td></tr>
      </tbody>
    </table>
    <h4>Key Points</h4>
    <ul>
      <li><strong>Ganciclovir toxicity:</strong> Myelosuppression (neutropenia, thrombocytopenia) ‚Äî monitor CBC</li>
      <li><strong>Renal dosing required:</strong> Adjust ganciclovir and valganciclovir for CrCl (see <a href="#renal-dosing" style="color: #0366d6;">Renal Dosing</a>)</li>
      <li><strong>Foscarnet:</strong> Alternative for ganciclovir-resistant CMV or intolerance. Nephrotoxic, electrolyte abnormalities.</li>
      <li><strong>Cidofovir:</strong> Third-line; significant nephrotoxicity (give with probenecid and hydration)</li>
    </ul>
    <h4>Prophylaxis vs. Preemptive Therapy (Transplant)</h4>
    <ul>
      <li><strong>Prophylaxis:</strong> Valganciclovir 900mg PO daily for 3-6 months post-transplant (high-risk: D+/R-)</li>
      <li><strong>Preemptive:</strong> Monitor CMV PCR weekly; treat when viremia detected before symptoms</li>
    </ul>
  </div>

  <button class="collapsible">Mycobacterium avium Complex (MAC)</button>
  <div class="panel">
    <h4>Risk Groups</h4>
    <ul>
      <li><strong>HIV:</strong> CD4 <50 cells/ŒºL</li>
      <li><strong>Other:</strong> Severe immunosuppression, particularly T-cell defects</li>
    </ul>
    <h4>Clinical Features (Disseminated MAC)</h4>
    <ul>
      <li>Fever, night sweats, weight loss</li>
      <li>Hepatosplenomegaly, lymphadenopathy</li>
      <li>Anemia, elevated alkaline phosphatase</li>
      <li>Diarrhea, abdominal pain</li>
    </ul>
    <h4>Diagnosis</h4>
    <ul>
      <li><strong>Blood culture:</strong> Gold standard for disseminated disease (isolator or BACTEC mycobacterial culture)</li>
      <li><strong>Bone marrow biopsy:</strong> If blood cultures negative and high suspicion</li>
      <li><strong>AFB stain and culture</strong> from involved sites (lymph node, liver, stool)</li>
    </ul>
    <h4>Treatment</h4>
    <table>
      <thead><tr><th>Regimen</th><th>Dose</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Clarithromycin</strong> (or Azithromycin)</td><td>500mg PO BID (Clarith) or 500-600mg PO daily (Azith)</td><td>Macrolide is cornerstone ‚Äî never use as monotherapy</td></tr>
        <tr><td><strong>Ethambutol</strong></td><td>15 mg/kg PO daily</td><td>Always combine with macrolide</td></tr>
        <tr><td><strong>¬± Rifabutin</strong></td><td>300mg PO daily</td><td>Add for severe disease; significant drug interactions (CYP3A4)</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Duration:</strong> Continue for at least 12 months AND until CD4 >100 for ‚â•6 months on ART.</p>
    <h4>Prophylaxis</h4>
    <ul>
      <li><strong>Indication:</strong> CD4 <50 cells/ŒºL (after ruling out active MAC)</li>
      <li><strong>Regimen:</strong> Azithromycin 1200mg PO weekly OR Clarithromycin 500mg PO BID</li>
      <li><strong>Stop when:</strong> CD4 >100 for ‚â•3 months on ART</li>
    </ul>
    <h4>Immune Reconstitution Inflammatory Syndrome (IRIS)</h4>
    <ul>
      <li>Can occur when starting ART with underlying MAC infection</li>
      <li>Presents with fever, lymphadenitis, worsening symptoms despite appropriate MAC treatment</li>
      <li>Manage with NSAIDs; severe cases may need steroids</li>
    </ul>
  </div>

  <button class="collapsible">Cryptococcal Meningitis</button>
  <div class="panel">
    <h4>Risk Groups</h4>
    <ul>
      <li><strong>HIV:</strong> CD4 <100 cells/ŒºL (most common)</li>
      <li><strong>Transplant recipients</strong></li>
      <li><strong>Corticosteroid use</strong></li>
      <li><strong>Cirrhosis, sarcoidosis</strong></li>
    </ul>
    <h4>Clinical Features</h4>
    <ul>
      <li>Subacute meningitis: Headache, fever, neck stiffness (may be subtle)</li>
      <li>Altered mental status, cranial nerve palsies</li>
      <li><strong>Elevated intracranial pressure</strong> ‚Äî major cause of morbidity/mortality</li>
      <li>May have pulmonary or disseminated disease</li>
    </ul>
    <h4>Diagnosis</h4>
    <table>
      <thead><tr><th>Test</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>Serum CrAg (Cryptococcal Antigen)</strong></td><td>Highly sensitive and specific (>95%); positive in disseminated disease</td></tr>
        <tr><td><strong>CSF CrAg</strong></td><td>Diagnostic for meningitis</td></tr>
        <tr><td><strong>CSF India ink</strong></td><td>Classic encapsulated yeast; less sensitive than CrAg</td></tr>
        <tr><td><strong>CSF culture</strong></td><td>Gold standard; takes days-weeks</td></tr>
        <tr><td><strong>Opening pressure</strong></td><td>Often elevated (>20-25 cm H2O); measure with every LP</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Cross-link:</strong> <a href="lab_values.html#csf" style="color: #0366d6;">üî¨ CSF Reference</a>, <a href="im_guide.html#meningitis" style="color: #0366d6;">üìö IMCRG: Meningitis</a></p>
    <h4>Treatment (HIV-Associated)</h4>
    <table>
      <thead><tr><th>Phase</th><th>Regimen</th><th>Duration</th></tr></thead>
      <tbody>
        <tr><td><strong>Induction</strong></td><td>Amphotericin B deoxycholate 0.7-1 mg/kg/day IV + Flucytosine 100 mg/kg/day PO divided q6h</td><td>‚â•2 weeks (until CSF sterile)</td></tr>
        <tr><td><strong>Consolidation</strong></td><td>Fluconazole 400mg PO daily</td><td>8 weeks</td></tr>
        <tr><td><strong>Maintenance</strong></td><td>Fluconazole 200mg PO daily</td><td>‚â•1 year, until CD4 >100 √ó 3mo + undetectable VL</td></tr>
      </tbody>
    </table>
    <h4>Liposomal Amphotericin B</h4>
    <ul>
      <li>3-4 mg/kg/day IV ‚Äî preferred if available (less nephrotoxic)</li>
      <li>WHO recommends single high-dose liposomal AmB (10 mg/kg) + flucytosine + fluconazole in resource-limited settings</li>
    </ul>
    <h4>Managing Elevated ICP ‚Äî CRITICAL</h4>
    <ul>
      <li><strong>Opening pressure >25 cm H2O:</strong> Remove CSF to reduce pressure to <20 or by 50%</li>
      <li><strong>Repeat LP daily</strong> if symptomatic or persistently elevated pressure</li>
      <li>Consider temporary lumbar drain or VP shunt if refractory</li>
      <li>Mannitol and steroids NOT effective and may be harmful</li>
    </ul>
    <h4>ART Timing</h4>
    <ul>
      <li><strong>Delay ART 4-6 weeks</strong> after starting antifungal therapy</li>
      <li>Early ART initiation increases mortality (IRIS, elevated ICP)</li>
    </ul>
  </div>

  <button class="collapsible">Toxoplasma gondii Encephalitis</button>
  <div class="panel">
    <h4>Risk Groups</h4>
    <ul>
      <li><strong>HIV:</strong> CD4 <100 cells/ŒºL with positive Toxoplasma IgG (reactivation)</li>
      <li><strong>Transplant recipients:</strong> Especially heart transplant (D+/R-)</li>
    </ul>
    <h4>Clinical Features</h4>
    <ul>
      <li>Headache, fever, altered mental status</li>
      <li>Focal neurologic deficits (hemiparesis, ataxia, cranial nerve palsies)</li>
      <li>Seizures</li>
    </ul>
    <h4>Diagnosis</h4>
    <ul>
      <li><strong>MRI Brain:</strong> Multiple ring-enhancing lesions, typically in basal ganglia. Surrounding edema.</li>
      <li><strong>Toxoplasma IgG:</strong> Usually positive (reactivation). Negative IgG makes diagnosis unlikely.</li>
      <li><strong>Response to empiric therapy:</strong> Clinical and radiographic improvement within 2 weeks supports diagnosis</li>
      <li><strong>Brain biopsy:</strong> If no response to treatment or atypical features</li>
    </ul>
    <h4>Differential: Toxoplasma vs. CNS Lymphoma</h4>
    <table>
      <thead><tr><th>Feature</th><th>Toxoplasmosis</th><th>Primary CNS Lymphoma</th></tr></thead>
      <tbody>
        <tr><td>Lesions</td><td>Multiple, basal ganglia</td><td>Often single, periventricular</td></tr>
        <tr><td>Toxo IgG</td><td>Usually positive</td><td>May be negative</td></tr>
        <tr><td>CD4 count</td><td>Usually <100</td><td>Usually <50</td></tr>
        <tr><td>CSF EBV PCR</td><td>Negative</td><td>Often positive</td></tr>
        <tr><td>Response to empiric Tx</td><td>Yes (2 weeks)</td><td>No</td></tr>
      </tbody>
    </table>
    <h4>Treatment</h4>
    <table>
      <thead><tr><th>Regimen</th><th>Dose</th><th>Duration</th></tr></thead>
      <tbody>
        <tr><td><strong>Pyrimethamine</strong></td><td>200mg PO √ó 1 load, then 50-75mg PO daily</td><td>‚â•6 weeks</td></tr>
        <tr><td><strong>Sulfadiazine</strong></td><td>1000-1500mg PO q6h</td><td>‚â•6 weeks</td></tr>
        <tr><td><strong>Leucovorin</strong></td><td>10-25mg PO daily</td><td>Continue with pyrimethamine (prevents bone marrow suppression)</td></tr>
      </tbody>
    </table>
    <h4>Alternative (Sulfa Allergy)</h4>
    <ul>
      <li><strong>Pyrimethamine + Clindamycin:</strong> Clindamycin 600mg IV/PO q6h + Pyrimethamine + Leucovorin</li>
      <li><strong>TMP-SMX:</strong> 5 mg/kg (TMP) IV/PO BID (alternative if available)</li>
    </ul>
    <h4>Maintenance Therapy</h4>
    <ul>
      <li>After ‚â•6 weeks acute therapy, continue at half doses as maintenance</li>
      <li>Discontinue when CD4 >200 for ‚â•6 months on ART</li>
    </ul>
    <h4>Prophylaxis</h4>
    <ul>
      <li><strong>Indication:</strong> CD4 <100 AND positive Toxoplasma IgG</li>
      <li><strong>Regimen:</strong> TMP-SMX 1 DS daily (also covers PCP)</li>
    </ul>
  </div>

  <button class="collapsible">Other Opportunistic Infections</button>
  <div class="panel">
    <h4>Histoplasmosis (Disseminated)</h4>
    <ul>
      <li><strong>Risk:</strong> CD4 <150; endemic areas (Ohio/Mississippi River valleys)</li>
      <li><strong>Features:</strong> Fever, weight loss, hepatosplenomegaly, pancytopenia, skin lesions</li>
      <li><strong>Diagnosis:</strong> Urine/serum Histoplasma antigen (very sensitive), blood culture (fungal isolator)</li>
      <li><strong>Treatment:</strong> Liposomal AmB 3 mg/kg/day IV √ó 1-2 weeks (induction), then itraconazole 200mg PO TID √ó 3 days, then BID √ó ‚â•12 months</li>
    </ul>
    <h4>Coccidioidomycosis (Disseminated)</h4>
    <ul>
      <li><strong>Risk:</strong> CD4 <250; endemic areas (Southwest US, Central America)</li>
      <li><strong>Features:</strong> Pneumonia, meningitis, skin lesions, bone involvement</li>
      <li><strong>Diagnosis:</strong> Coccidioides IgM/IgG, urine/serum antigen, culture</li>
      <li><strong>Treatment:</strong> Fluconazole 400-800mg daily (non-meningeal) or AmB (severe). Meningitis: Fluconazole 800-1200mg daily lifelong.</li>
    </ul>
    <h4>Progressive Multifocal Leukoencephalopathy (PML)</h4>
    <ul>
      <li><strong>Cause:</strong> JC virus reactivation</li>
      <li><strong>Risk:</strong> CD4 <100; also natalizumab, rituximab</li>
      <li><strong>Features:</strong> Focal neurologic deficits, cognitive decline, no fever/headache</li>
      <li><strong>Diagnosis:</strong> MRI (white matter lesions, no enhancement, no mass effect), CSF JC virus PCR</li>
      <li><strong>Treatment:</strong> No specific antiviral. Immune reconstitution (ART) is only treatment. May develop IRIS.</li>
    </ul>
    <h4>Microsporidiosis</h4>
    <ul>
      <li><strong>Risk:</strong> CD4 <100</li>
      <li><strong>Features:</strong> Chronic watery diarrhea, wasting</li>
      <li><strong>Diagnosis:</strong> Modified trichrome stain of stool, PCR</li>
      <li><strong>Treatment:</strong> Albendazole 400mg PO BID + ART</li>
    </ul>
  </div>
</section>

<!-- ANTIBIOGRAM GUIDANCE -->
<section id="antibiogram-guide">
  <h2>Antibiogram Interpretation & Use</h2>
  <p class="muted">Local resistance patterns guide empiric therapy. The antibiogram is your hospital's susceptibility report card.</p>

  <button class="collapsible">What is an Antibiogram?</button>
  <div class="panel">
    <h4>Definition</h4>
    <p>An antibiogram is a summary of antimicrobial susceptibility test results for organisms isolated at a specific institution over a defined period (usually 1 year). It shows the percentage of isolates susceptible to each antibiotic tested.</p>
    <h4>Why It Matters</h4>
    <ul>
      <li>Resistance patterns vary significantly by hospital, unit, and region</li>
      <li>National guidelines provide general recommendations; local antibiogram provides YOUR hospital's data</li>
      <li>Empiric therapy should target >80-90% susceptibility for serious infections</li>
    </ul>
    <h4>Limitations</h4>
    <ul>
      <li>Reflects past patterns (typically 1 year old data)</li>
      <li>Aggregates all isolates ‚Äî doesn't distinguish ICU vs. floor, inpatient vs. outpatient</li>
      <li>May not reflect individual patient's prior cultures or risk factors</li>
      <li>Only includes tested isolates (selection bias)</li>
    </ul>
  </div>

  <button class="collapsible">How to Read an Antibiogram</button>
  <div class="panel">
    <h4>Example Antibiogram (Simplified)</h4>
    <table>
      <thead><tr><th>Organism</th><th>Amp</th><th>Pip-Tazo</th><th>Ceftriaxone</th><th>Cefepime</th><th>Cipro</th><th>Gent</th><th>TMP-SMX</th></tr></thead>
      <tbody>
        <tr><td><strong>E. coli (n=500)</strong></td><td>55%</td><td>92%</td><td>88%</td><td>94%</td><td>72%</td><td>89%</td><td>75%</td></tr>
        <tr><td><strong>Klebsiella pneumoniae (n=200)</strong></td><td>0%</td><td>88%</td><td>85%</td><td>91%</td><td>90%</td><td>92%</td><td>85%</td></tr>
        <tr><td><strong>Pseudomonas aeruginosa (n=150)</strong></td><td>-</td><td>85%</td><td>-</td><td>87%</td><td>78%</td><td>88%</td><td>-</td></tr>
        <tr><td><strong>MSSA (n=300)</strong></td><td>-</td><td>100%</td><td>100%</td><td>100%</td><td>-</td><td>100%</td><td>98%</td></tr>
        <tr><td><strong>MRSA (n=100)</strong></td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>-</td><td>-</td><td>95%</td></tr>
      </tbody>
    </table>
    <p class="small">Numbers represent % of isolates susceptible. "-" = not tested or not applicable.</p>
    <h4>Interpreting the Numbers</h4>
    <ul>
      <li><strong>>90%:</strong> Excellent choice for empiric therapy</li>
      <li><strong>80-90%:</strong> Acceptable for non-severe infections; consider alternatives for severe infections</li>
      <li><strong><80%:</strong> Generally avoid for empiric therapy; may use if culture-directed</li>
    </ul>
  </div>

  <button class="collapsible">Applying Antibiogram to Clinical Decisions</button>
  <div class="panel">
    <h4>Scenario 1: Uncomplicated UTI</h4>
    <p>Your antibiogram shows E. coli susceptibility: TMP-SMX 75%, Ciprofloxacin 72%, Nitrofurantoin 95%</p>
    <ul>
      <li><strong>Best empiric choice:</strong> Nitrofurantoin (95% susceptibility)</li>
      <li>Avoid TMP-SMX and ciprofloxacin empirically (<80%)</li>
      <li>This is why IDSA now recommends nitrofurantoin first-line for uncomplicated cystitis</li>
    </ul>
    
    <h4>Scenario 2: Hospital-Acquired Pneumonia</h4>
    <p>High-risk patient, your antibiogram shows: P. aeruginosa susceptibility to pip-tazo 85%, cefepime 87%, meropenem 95%</p>
    <ul>
      <li>For severe infection, want >90% coverage</li>
      <li><strong>Best empiric choice:</strong> Meropenem (or combination therapy with pip-tazo + aminoglycoside for double coverage)</li>
    </ul>
    
    <h4>Scenario 3: Skin/Soft Tissue Infection</h4>
    <p>Your antibiogram shows MRSA prevalence 35% of all S. aureus isolates</p>
    <ul>
      <li>If MRSA prevalence >10-20%, consider empiric MRSA coverage (vancomycin, doxycycline, TMP-SMX) for purulent SSTIs</li>
      <li>If MRSA prevalence <10%, empiric MSSA coverage (cephalexin, dicloxacillin) may be reasonable</li>
    </ul>
    
    <h4>General Principles</h4>
    <ul>
      <li><strong>Match severity to susceptibility threshold:</strong> Severe infections need >90% coverage; mild infections may accept lower</li>
      <li><strong>Consider individual risk factors:</strong> Recent antibiotics, prior cultures, healthcare exposure may shift probability toward resistance</li>
      <li><strong>De-escalate when cultures return:</strong> Antibiogram guides empiric therapy; definitive therapy is culture-directed</li>
    </ul>
  </div>

  <button class="collapsible">ESBL and Resistance Patterns to Watch</button>
  <div class="panel">
    <h4>ESBL (Extended-Spectrum Beta-Lactamase) Producers</h4>
    <ul>
      <li><strong>Organisms:</strong> E. coli, Klebsiella, Proteus</li>
      <li><strong>Resistance:</strong> All penicillins and cephalosporins (including 3rd/4th gen), aztreonam</li>
      <li><strong>Treatment:</strong> Carbapenems (meropenem, ertapenem); pip-tazo may work for UTI with low inoculum</li>
      <li><strong>Clue on antibiogram:</strong> Susceptible to cefepime in vitro but cephalosporin failure clinically. Some labs report "ESBL screen positive."</li>
    </ul>
    
    <h4>AmpC Producers</h4>
    <ul>
      <li><strong>Organisms:</strong> "SPICE" ‚Äî Serratia, Providencia, Indole-positive Proteus, Citrobacter, Enterobacter</li>
      <li><strong>Risk:</strong> May appear susceptible to 3rd-gen cephalosporins but develop resistance during therapy</li>
      <li><strong>Treatment:</strong> Cefepime (stable to AmpC), carbapenems, fluoroquinolones if susceptible</li>
    </ul>
    
    <h4>CRE (Carbapenem-Resistant Enterobacteriaceae)</h4>
    <ul>
      <li><strong>Mechanisms:</strong> KPC (most common in US), NDM, OXA-48</li>
      <li><strong>Treatment:</strong> Ceftazidime-avibactam (KPC), meropenem-vaborbactam, combination therapy; ID consult recommended</li>
    </ul>
    
    <h4>MRSA</h4>
    <ul>
      <li>Check your antibiogram for MRSA prevalence (% of S. aureus that is MRSA)</li>
      <li>Also check susceptibility to clindamycin (D-test for inducible resistance), TMP-SMX, doxycycline</li>
    </ul>
    
    <h4>VRE (Vancomycin-Resistant Enterococcus)</h4>
    <ul>
      <li>Usually E. faecium (E. faecalis resistance less common)</li>
      <li><strong>Treatment:</strong> Linezolid, daptomycin (not for pulmonary infections)</li>
    </ul>
  </div>

  <button class="collapsible">Stratified Antibiograms</button>
  <div class="panel">
    <h4>Why Stratification Matters</h4>
    <p>A single hospital antibiogram aggregates very different patient populations. Resistance patterns differ significantly between:</p>
    <ul>
      <li>ICU vs. general medical floors</li>
      <li>Inpatient vs. outpatient (ED, clinic)</li>
      <li>Different specimen types (blood vs. urine vs. respiratory)</li>
      <li>Community-onset vs. hospital-onset infections</li>
    </ul>
    
    <h4>Example: E. coli Cipro Susceptibility</h4>
    <table>
      <thead><tr><th>Population</th><th>Cipro Susceptibility</th></tr></thead>
      <tbody>
        <tr><td>Overall hospital</td><td>72%</td></tr>
        <tr><td>Outpatient urine (ED)</td><td>85%</td></tr>
        <tr><td>Inpatient urine (floor)</td><td>68%</td></tr>
        <tr><td>ICU urine</td><td>55%</td></tr>
        <tr><td>Blood cultures</td><td>60%</td></tr>
      </tbody>
    </table>
    <p class="small">Using the stratified data, you might use cipro empirically for an ED UTI (85%) but not for an ICU patient (55%).</p>
    
    <h4>Ask Your Pharmacy/Micro Lab</h4>
    <ul>
      <li>Many hospitals now produce unit-specific or specimen-specific antibiograms</li>
      <li>If not available, ask ‚Äî this data may exist but not be widely distributed</li>
    </ul>
  </div>
</section>

<!-- OPAT GUIDE -->
<section id="opat">
  <h2>Outpatient Parenteral Antimicrobial Therapy (OPAT)</h2>
  <p class="muted">Criteria for safe discharge on IV antibiotics, monitoring, and common regimens. Cross-reference: <a href="#duration-therapy" style="color: #0366d6;">Duration of Therapy</a>, <a href="#renal-dosing" style="color: #0366d6;">Renal Dosing</a></p>

  <button class="collapsible">Patient Selection Criteria</button>
  <div class="panel">
    <h4>Appropriate Candidates</h4>
    <ul>
      <li>Infection requiring IV antibiotics that cannot be treated with oral alternatives</li>
      <li>Clinically stable (afebrile, hemodynamically stable, no acute decompensation)</li>
      <li>Reliable IV access (PICC line, midline, or port)</li>
      <li>Able to manage home infusion or has caregiver support</li>
      <li>Access to OPAT services (infusion center, home health, or self-administration)</li>
      <li>Reliable follow-up and monitoring capability</li>
    </ul>
    
    <h4>Relative Contraindications</h4>
    <ul>
      <li>Active IV drug use (high risk of line misuse) ‚Äî consider supervised infusion or oral alternatives</li>
      <li>Unstable housing or lack of refrigeration (for some drugs)</li>
      <li>Cognitive impairment without reliable caregiver</li>
      <li>History of severe allergic reaction or line complications</li>
      <li>Ongoing diagnostic uncertainty</li>
    </ul>
    
    <h4>Before Discharge Checklist</h4>
    <ul>
      <li>‚ñ° Source control achieved (if applicable)</li>
      <li>‚ñ° PICC/Midline placed and functioning</li>
      <li>‚ñ° Culture data available and therapy appropriate</li>
      <li>‚ñ° Duration of therapy defined</li>
      <li>‚ñ° OPAT referral placed (infusion services, home health)</li>
      <li>‚ñ° Labs scheduled (see monitoring below)</li>
      <li>‚ñ° Follow-up appointments (ID clinic, PCP)</li>
      <li>‚ñ° Patient/caregiver education completed</li>
      <li>‚ñ° Drug supply secured (prior authorization if needed)</li>
    </ul>
  </div>

  <button class="collapsible">OPAT-Friendly Antibiotics</button>
  <div class="panel">
    <h4>Once-Daily IV Antibiotics (Preferred for OPAT)</h4>
    <table>
      <thead><tr><th>Drug</th><th>Typical Dose</th><th>Common Indications</th><th>Key Monitoring</th></tr></thead>
      <tbody>
        <tr><td><strong>Ceftriaxone</strong></td><td>1-2g IV q24h</td><td>Bone/joint, endocarditis (Strep), UTI, skin</td><td>CBC, LFTs; well-tolerated</td></tr>
        <tr><td><strong>Ertapenem</strong></td><td>1g IV q24h</td><td>Intra-abdominal, diabetic foot (polymicrobial), ESBL</td><td>CBC; seizure risk (rare)</td></tr>
        <tr><td><strong>Daptomycin</strong></td><td>6-10 mg/kg IV q24h</td><td>MRSA bacteremia, endocarditis, bone/joint</td><td>CK weekly (myopathy), BMP</td></tr>
        <tr><td><strong>Dalbavancin</strong></td><td>1500mg IV √ó 1 or 1000mg then 500mg week 2</td><td>ABSSSI, bone/joint (selected cases)</td><td>Minimal; single/two-dose regimen</td></tr>
        <tr><td><strong>Oritavancin</strong></td><td>1200mg IV √ó 1</td><td>ABSSSI</td><td>Single dose; avoid with warfarin (interferes with INR)</td></tr>
      </tbody>
    </table>
    
    <h4>Antibiotics Requiring More Frequent Dosing</h4>
    <table>
      <thead><tr><th>Drug</th><th>Typical Dose</th><th>OPAT Considerations</th></tr></thead>
      <tbody>
        <tr><td><strong>Vancomycin</strong></td><td>15-20 mg/kg IV q8-12h</td><td>Requires trough monitoring; consider AUC-based dosing. Nephrotoxic.</td></tr>
        <tr><td><strong>Cefazolin</strong></td><td>2g IV q8h (or 2g q12h with probenecid)</td><td>MSSA bone/joint, endocarditis. Can give via elastomeric pump.</td></tr>
        <tr><td><strong>Cefepime</strong></td><td>2g IV q8h (or extended infusion)</td><td>Pseudomonas coverage. Neurotoxicity in renal impairment.</td></tr>
        <tr><td><strong>Piperacillin-Tazobactam</strong></td><td>3.375-4.5g IV q6-8h</td><td>Broad-spectrum; requires frequent dosing or extended infusion.</td></tr>
        <tr><td><strong>Ampicillin</strong></td><td>2g IV q4h</td><td>Enterococcal infections, Listeria. Difficult for OPAT due to frequent dosing.</td></tr>
      </tbody>
    </table>
    
    <h4>Oral Alternatives to Consider (Avoid OPAT if Possible)</h4>
    <p>Per OVIVA trial and other data, oral antibiotics with excellent bioavailability may be equivalent to IV for many infections including osteomyelitis:</p>
    <ul>
      <li><strong>Fluoroquinolones:</strong> Levofloxacin, ciprofloxacin (excellent bioavailability)</li>
      <li><strong>Linezolid:</strong> 100% bioavailability; MRSA coverage</li>
      <li><strong>TMP-SMX:</strong> Good for MRSA, some GNRs</li>
      <li><strong>Doxycycline:</strong> MRSA SSTIs, some respiratory</li>
      <li><strong>Metronidazole:</strong> Anaerobic coverage</li>
    </ul>
    <p class="small"><strong>Bottom Line:</strong> Before committing to OPAT, always ask: "Is there an oral option with equivalent efficacy?"</p>
  </div>

  <button class="collapsible">Laboratory Monitoring on OPAT</button>
  <div class="panel">
    <h4>General Monitoring Schedule</h4>
    <table>
      <thead><tr><th>Timeframe</th><th>Labs</th></tr></thead>
      <tbody>
        <tr><td>Baseline (before discharge)</td><td>CBC, BMP, LFTs</td></tr>
        <tr><td>Weekly</td><td>CBC, BMP (Cr), LFTs</td></tr>
        <tr><td>As indicated</td><td>Drug levels, CK, additional tests per drug</td></tr>
      </tbody>
    </table>
    
    <h4>Drug-Specific Monitoring</h4>
    <table>
      <thead><tr><th>Drug</th><th>Specific Monitoring</th><th>Frequency</th></tr></thead>
      <tbody>
        <tr><td><strong>Vancomycin</strong></td><td>Trough (or AUC), BMP (nephrotoxicity)</td><td>Trough: 48-72h after start, then weekly. BMP weekly.</td></tr>
        <tr><td><strong>Aminoglycosides</strong></td><td>Random level (Hartford), BMP, audiometry if prolonged</td><td>Level per nomogram; BMP weekly</td></tr>
        <tr><td><strong>Daptomycin</strong></td><td>CK (myopathy)</td><td>Weekly; hold if CK >10√ó ULN or symptoms</td></tr>
        <tr><td><strong>Linezolid</strong></td><td>CBC (myelosuppression), especially platelets</td><td>Weekly; risk increases after 2 weeks</td></tr>
        <tr><td><strong>Beta-lactams</strong></td><td>CBC (neutropenia, eosinophilia), LFTs, BMP</td><td>Weekly; neutropenia more common with prolonged use</td></tr>
        <tr><td><strong>TMP-SMX (IV)</strong></td><td>CBC, BMP (hyperkalemia), LFTs</td><td>Weekly</td></tr>
        <tr><td><strong>Amphotericin B</strong></td><td>BMP (K, Mg, Cr), CBC</td><td>Daily initially, then 2-3√ó weekly</td></tr>
      </tbody>
    </table>
    
    <h4>When to Hold and Call</h4>
    <ul>
      <li><strong>Fever or new symptoms:</strong> Treatment failure, new infection, drug reaction</li>
      <li><strong>Rash:</strong> Drug allergy (may need to switch)</li>
      <li><strong>Line issues:</strong> Redness, swelling, pain at site; difficulty infusing</li>
      <li><strong>Lab abnormalities:</strong> Significant Cr rise, cytopenias, LFT elevations >3√ó ULN</li>
    </ul>
  </div>

  <button class="collapsible">Common OPAT Regimens by Indication</button>
  <div class="panel">
    <h4>Osteomyelitis</h4>
    <table>
      <thead><tr><th>Organism</th><th>IV Option</th><th>Oral Option</th><th>Duration</th></tr></thead>
      <tbody>
        <tr><td><strong>MSSA</strong></td><td>Cefazolin 2g IV q8h</td><td>Cephalexin 1g PO QID or Dicloxacillin 500mg PO QID</td><td>6 weeks</td></tr>
        <tr><td><strong>MRSA</strong></td><td>Vancomycin or Daptomycin</td><td>Linezolid 600mg PO BID or TMP-SMX DS 2 tabs PO BID + Rifampin</td><td>6 weeks</td></tr>
        <tr><td><strong>Pseudomonas</strong></td><td>Cefepime 2g IV q8h or Ceftazidime</td><td>Ciprofloxacin 750mg PO BID (if susceptible)</td><td>6 weeks</td></tr>
      </tbody>
    </table>
    
    <h4>Endocarditis (Native Valve)</h4>
    <table>
      <thead><tr><th>Organism</th><th>Regimen</th><th>Duration</th></tr></thead>
      <tbody>
        <tr><td><strong>Viridans Strep (penicillin-susceptible)</strong></td><td>Ceftriaxone 2g IV q24h</td><td>4 weeks (or 2 weeks with gentamicin synergy)</td></tr>
        <tr><td><strong>MSSA</strong></td><td>Cefazolin 2g IV q8h</td><td>6 weeks</td></tr>
        <tr><td><strong>MRSA</strong></td><td>Vancomycin or Daptomycin 8-10 mg/kg IV q24h</td><td>6 weeks</td></tr>
        <tr><td><strong>Enterococcus (ampicillin-susceptible)</strong></td><td>Ampicillin 2g IV q4h + Ceftriaxone 2g IV q12h</td><td>6 weeks</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Note:</strong> Endocarditis OPAT requires close ID follow-up and careful patient selection.</p>
    
    <h4>Septic Arthritis (Native Joint)</h4>
    <ul>
      <li><strong>MSSA:</strong> Cefazolin 2g IV q8h ‚Üí 2-4 weeks total (with adequate drainage)</li>
      <li><strong>MRSA:</strong> Vancomycin (trough 15-20) or Daptomycin ‚Üí 2-4 weeks total</li>
      <li><strong>GNR:</strong> Based on susceptibilities; 2-4 weeks total</li>
    </ul>
    
    <h4>Intra-Abdominal Infections</h4>
    <ul>
      <li><strong>Ertapenem 1g IV q24h:</strong> Excellent once-daily option for polymicrobial infections after source control</li>
      <li><strong>Duration:</strong> 4-7 days after source control (per STOP-IT trial)</li>
    </ul>
  </div>

  <button class="collapsible">Line Care and Complications</button>
  <div class="panel">
    <h4>Types of IV Access for OPAT</h4>
    <table>
      <thead><tr><th>Type</th><th>Duration</th><th>Pros</th><th>Cons</th></tr></thead>
      <tbody>
        <tr><td><strong>PICC</strong></td><td>Weeks to months</td><td>Durable, easy to place, suitable for most infusions</td><td>DVT risk (~3-5%), infection risk, may not be placed if small veins</td></tr>
        <tr><td><strong>Midline</strong></td><td>1-4 weeks</td><td>Lower DVT risk than PICC, no chest X-ray needed</td><td>Cannot infuse vesicants, shorter duration</td></tr>
        <tr><td><strong>Port</strong></td><td>Months to years</td><td>Very durable, lower infection rate when not accessed</td><td>Requires surgical placement, more expensive</td></tr>
      </tbody>
    </table>
    
    <h4>Line Complications</h4>
    <ul>
      <li><strong>Occlusion:</strong> Unable to infuse or withdraw. Try TPA (alteplase) instillation.</li>
      <li><strong>Infection:</strong> Exit site infection vs. CLABSI. Exit site: local care, may salvage line. CLABSI: usually requires line removal.</li>
      <li><strong>Thrombosis:</strong> Arm swelling, pain. Confirm with ultrasound. Anticoagulate; line removal often not necessary if functional.</li>
      <li><strong>Dislodgement:</strong> Confirm position; may need replacement.</li>
    </ul>
    
    <h4>Patient Education</h4>
    <ul>
      <li>Keep dressing clean and dry</li>
      <li>Flush line per protocol (usually heparin or saline)</li>
      <li>Signs to report: fever, redness/swelling at site, arm swelling, difficulty infusing</li>
      <li>Never use line for non-prescribed purposes</li>
    </ul>
  </div>
</section>

<!-- PROPHYLAXIS TABLES -->
<section id="prophylaxis">
  <h2>Antimicrobial Prophylaxis Tables</h2>
  <p class="muted">Surgical prophylaxis, neutropenia/transplant prophylaxis, and asplenia management.</p>

  <button class="collapsible">Surgical Antimicrobial Prophylaxis</button>
  <div class="panel">
    <h4>General Principles</h4>
    <ul>
      <li><strong>Timing:</strong> Give within 60 minutes before incision (120 min for vancomycin and fluoroquinolones)</li>
      <li><strong>Re-dosing:</strong> Re-dose intraoperatively for prolonged procedures (>2 half-lives) or significant blood loss</li>
      <li><strong>Duration:</strong> Single dose or ‚â§24 hours postoperatively for most procedures</li>
      <li><strong>No benefit</strong> from continuing antibiotics based on drains, catheters, or "until lines removed"</li>
    </ul>
    
    <h4>Surgical Prophylaxis by Procedure</h4>
    <table>
      <thead><tr><th>Procedure</th><th>First-Line</th><th>PCN Allergy</th><th>MRSA Risk*</th></tr></thead>
      <tbody>
        <tr><td><strong>Cardiac (sternotomy, CABG, valve)</strong></td><td>Cefazolin 2g IV</td><td>Vancomycin 15 mg/kg</td><td>Add Vancomycin</td></tr>
        <tr><td><strong>Orthopedic (arthroplasty, spine fusion, ORIF)</strong></td><td>Cefazolin 2g IV</td><td>Vancomycin 15 mg/kg</td><td>Add Vancomycin</td></tr>
        <tr><td><strong>Vascular (arterial, lower extremity amputation)</strong></td><td>Cefazolin 2g IV</td><td>Vancomycin 15 mg/kg</td><td>Add Vancomycin</td></tr>
        <tr><td><strong>Colorectal</strong></td><td>Cefazolin 2g + Metronidazole 500mg IV (or Ertapenem 1g)</td><td>Clindamycin 900mg + Gentamicin; or Metronidazole + Fluoroquinolone</td><td>Add Vancomycin</td></tr>
        <tr><td><strong>Appendectomy</strong></td><td>Cefazolin 2g + Metronidazole 500mg (or Cefoxitin 2g)</td><td>Metronidazole + Fluoroquinolone</td><td>‚Äî</td></tr>
        <tr><td><strong>Cholecystectomy (high-risk only)</strong></td><td>Cefazolin 2g IV</td><td>Clindamycin + Gentamicin</td><td>‚Äî</td></tr>
        <tr><td><strong>Hysterectomy</strong></td><td>Cefazolin 2g IV</td><td>Clindamycin 900mg + Gentamicin</td><td>‚Äî</td></tr>
        <tr><td><strong>Cesarean section</strong></td><td>Cefazolin 2g IV (before incision)</td><td>Clindamycin 900mg + Gentamicin</td><td>‚Äî</td></tr>
        <tr><td><strong>Craniotomy</strong></td><td>Cefazolin 2g IV</td><td>Vancomycin 15 mg/kg</td><td>Add Vancomycin</td></tr>
        <tr><td><strong>Head and neck (clean-contaminated)</strong></td><td>Cefazolin 2g + Metronidazole 500mg (or Ampicillin-Sulbactam 3g)</td><td>Clindamycin 900mg</td><td>‚Äî</td></tr>
        <tr><td><strong>Urologic (clean-contaminated)</strong></td><td>Cefazolin 2g IV or Fluoroquinolone</td><td>Fluoroquinolone or Aminoglycoside</td><td>‚Äî</td></tr>
      </tbody>
    </table>
    <p class="small">*MRSA risk factors: known MRSA colonization, recent MRSA infection, institution with high MRSA prevalence. Add vancomycin to (not replace) cefazolin.</p>
    
    <h4>Weight-Based Dosing</h4>
    <ul>
      <li><strong>Cefazolin:</strong> 2g if <120 kg; 3g if ‚â•120 kg</li>
      <li><strong>Vancomycin:</strong> 15 mg/kg (round to nearest 250mg); max 2g single dose</li>
    </ul>
    
    <h4>Re-dosing Intervals</h4>
    <table>
      <thead><tr><th>Drug</th><th>Re-dose Interval</th></tr></thead>
      <tbody>
        <tr><td>Cefazolin</td><td>Every 4 hours</td></tr>
        <tr><td>Cefoxitin</td><td>Every 2 hours</td></tr>
        <tr><td>Ampicillin-Sulbactam</td><td>Every 2 hours</td></tr>
        <tr><td>Clindamycin</td><td>Every 6 hours</td></tr>
        <tr><td>Metronidazole</td><td>Every 8 hours</td></tr>
        <tr><td>Vancomycin</td><td>Not typically re-dosed (long half-life)</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Cross-link:</strong> <a href="im_guide.html#periop" style="color: #0366d6;">üìö IMCRG: Perioperative Management</a></p>
  </div>

  <button class="collapsible">Neutropenic Fever Prophylaxis</button>
  <div class="panel">
    <h4>Definitions</h4>
    <ul>
      <li><strong>Neutropenia:</strong> ANC <500 cells/ŒºL, or <1000 and expected to fall to <500</li>
      <li><strong>Prolonged neutropenia:</strong> >7 days</li>
      <li><strong>Profound neutropenia:</strong> ANC <100 cells/ŒºL</li>
    </ul>
    
    <h4>Antibacterial Prophylaxis</h4>
    <table>
      <thead><tr><th>Risk Group</th><th>Prophylaxis</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>High-risk</strong> (expected prolonged/profound neutropenia: AML induction, HSCT conditioning)</td><td>Levofloxacin 500mg PO daily</td><td>Start with chemotherapy; reduces GNR bacteremia. Continue until ANC recovery or fever develops.</td></tr>
        <tr><td><strong>Standard-risk</strong> (most solid tumor chemo)</td><td>Generally not recommended</td><td>Risk does not outweigh benefit of fluoroquinolone exposure.</td></tr>
      </tbody>
    </table>
    
    <h4>Antifungal Prophylaxis</h4>
    <table>
      <thead><tr><th>Setting</th><th>Regimen</th><th>Target Organisms</th></tr></thead>
      <tbody>
        <tr><td><strong>AML induction, MDS</strong></td><td>Posaconazole 300mg PO daily (or 200mg TID suspension)</td><td>Candida + Aspergillus (mold-active)</td></tr>
        <tr><td><strong>Allogeneic HSCT (pre-engraftment)</strong></td><td>Fluconazole 400mg PO daily OR Posaconazole/Voriconazole</td><td>Candida; mold-active agents if high Aspergillus risk</td></tr>
        <tr><td><strong>Allogeneic HSCT (with GVHD)</strong></td><td>Posaconazole 300mg PO daily</td><td>Candida + Aspergillus (high mold risk)</td></tr>
        <tr><td><strong>Autologous HSCT</strong></td><td>Fluconazole 400mg PO daily</td><td>Candida (lower mold risk)</td></tr>
      </tbody>
    </table>
    
    <h4>Antiviral Prophylaxis</h4>
    <table>
      <thead><tr><th>Indication</th><th>Regimen</th><th>Notes</th></tr></thead>
      <tbody>
        <tr><td><strong>HSV seropositive + high-intensity chemo or HSCT</strong></td><td>Acyclovir 400mg PO BID or Valacyclovir 500mg PO daily</td><td>Prevents HSV reactivation (mucositis, esophagitis)</td></tr>
        <tr><td><strong>CMV high-risk (D+/R- transplant)</strong></td><td>Valganciclovir 900mg PO daily OR preemptive monitoring</td><td>See CMV section above</td></tr>
      </tbody>
    </table>
    
    <h4>PCP Prophylaxis in Hematologic Malignancy</h4>
    <ul>
      <li><strong>Indications:</strong> ALL, alemtuzumab, fludarabine, high-dose steroids (‚â•20 mg √ó ‚â•4 weeks), allogeneic HSCT</li>
      <li><strong>Regimen:</strong> TMP-SMX 1 DS daily or 1 DS 3√ó weekly</li>
    </ul>
  </div>

  <button class="collapsible">Asplenia / Hyposplenia Prophylaxis</button>
  <div class="panel">
    <h4>High-Risk Organisms</h4>
    <ul>
      <li><strong>Encapsulated bacteria:</strong> <em>Streptococcus pneumoniae</em> (most common), <em>Haemophilus influenzae</em>, <em>Neisseria meningitidis</em></li>
      <li><strong>Other:</strong> <em>Capnocytophaga canimorsus</em> (dog bites), <em>Babesia</em> (endemic areas), <em>Plasmodium</em> (malaria)</li>
    </ul>
    <p><strong>Overwhelming Post-Splenectomy Infection (OPSI):</strong> Fulminant sepsis with high mortality (50-70%). Risk is lifelong but highest in first 2 years post-splenectomy.</p>
    
    <h4>Vaccinations (Critical)</h4>
    <table>
      <thead><tr><th>Vaccine</th><th>Timing (Elective Splenectomy)</th><th>Timing (Emergent/Unvaccinated)</th></tr></thead>
      <tbody>
        <tr><td><strong>Pneumococcal (PCV20 or PCV15 ‚Üí PPSV23)</strong></td><td>‚â•2 weeks pre-op</td><td>‚â•2 weeks post-op. PCV15 then PPSV23 ‚â•8 weeks later.</td></tr>
        <tr><td><strong>Meningococcal (MenACWY + MenB)</strong></td><td>‚â•2 weeks pre-op</td><td>‚â•2 weeks post-op</td></tr>
        <tr><td><strong>Haemophilus influenzae type b (Hib)</strong></td><td>‚â•2 weeks pre-op</td><td>‚â•2 weeks post-op</td></tr>
        <tr><td><strong>Influenza</strong></td><td>Annually</td><td>Annually</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Note:</strong> If splenectomy is urgent, vaccinate ‚â•2 weeks post-op (immune response is suboptimal immediately after surgery).</p>
    
    <h4>Antibiotic Prophylaxis</h4>
    <table>
      <thead><tr><th>Setting</th><th>Recommendation</th></tr></thead>
      <tbody>
        <tr><td><strong>Children <5 years</strong></td><td>Penicillin VK 125-250mg PO BID until age 5 (at minimum)</td></tr>
        <tr><td><strong>Adults post-splenectomy</strong></td><td>Consider prophylaxis for 1-2 years (especially if immunocompromised). Amoxicillin 250-500mg PO daily or Penicillin VK 250mg PO BID.</td></tr>
        <tr><td><strong>Lifelong prophylaxis</strong></td><td>Consider if: immunocompromised, history of OPSI, poor antibody response to vaccination</td></tr>
      </tbody>
    </table>
    
    <h4>Patient Education ‚Äî Wallet Card</h4>
    <ul>
      <li>Carry a wallet card indicating asplenic status</li>
      <li><strong>Fever = Emergency:</strong> Seek immediate medical attention for any fever. Do not wait.</li>
      <li><strong>Standby antibiotics:</strong> Prescribe amoxicillin-clavulanate 875/125mg to take at first sign of illness if unable to reach medical care quickly</li>
      <li><strong>Animal bites:</strong> High risk for <em>Capnocytophaga</em>; seek care immediately and start antibiotics</li>
      <li><strong>Travel:</strong> Malaria prophylaxis essential in endemic areas; Babesia risk in Northeast US</li>
    </ul>
    
    <h4>Management of Febrile Asplenic Patient</h4>
    <ul>
      <li><strong>Empiric antibiotics IMMEDIATELY</strong> ‚Äî do not wait for cultures</li>
      <li><strong>Regimen:</strong> Ceftriaxone 2g IV + Vancomycin (if MRSA risk or critically ill)</li>
      <li>Blood cultures, but do not delay antibiotics</li>
      <li>Consider ICU admission for close monitoring</li>
    </ul>
  </div>

  <button class="collapsible">Endocarditis Prophylaxis</button>
  <div class="panel">
    <h4>Who Needs Prophylaxis?</h4>
    <p>Prophylaxis is recommended only for patients at <strong>highest risk</strong> of adverse outcomes from endocarditis:</p>
    <ul>
      <li>Prosthetic cardiac valve or prosthetic material used for valve repair</li>
      <li>Previous infective endocarditis</li>
      <li>Certain congenital heart diseases:
        <ul>
          <li>Unrepaired cyanotic CHD</li>
          <li>Repaired CHD with residual defects at or near prosthetic material</li>
          <li>Repaired CHD with prosthetic material <6 months post-procedure</li>
        </ul>
      </li>
      <li>Cardiac transplant recipients with valvulopathy</li>
    </ul>
    <p class="small"><strong>Note:</strong> MVP, bicuspid aortic valve, and most other valve disorders do NOT require prophylaxis per current AHA guidelines.</p>
    
    <h4>Which Procedures?</h4>
    <ul>
      <li><strong>Dental:</strong> Procedures involving gingival tissue, periapical region of teeth, or perforation of oral mucosa</li>
      <li><strong>NOT indicated:</strong> Routine GI or GU procedures (including EGD, colonoscopy)</li>
    </ul>
    
    <h4>Regimens</h4>
    <table>
      <thead><tr><th>Situation</th><th>Regimen</th><th>Dose (30-60 min before procedure)</th></tr></thead>
      <tbody>
        <tr><td><strong>Standard</strong></td><td>Amoxicillin</td><td>2g PO</td></tr>
        <tr><td><strong>Unable to take PO</strong></td><td>Ampicillin OR Cefazolin/Ceftriaxone</td><td>2g IV/IM OR 1g IV/IM</td></tr>
        <tr><td><strong>Penicillin allergy (non-severe)</strong></td><td>Cephalexin</td><td>2g PO</td></tr>
        <tr><td><strong>Penicillin allergy (severe/anaphylaxis)</strong></td><td>Azithromycin OR Clindamycin</td><td>500mg PO OR 600mg PO</td></tr>
      </tbody>
    </table>
    <p class="small"><strong>Cross-link:</strong> <a href="im_guide.html#endocarditis" style="color: #0366d6;">üìö IMCRG: Infective Endocarditis</a>, <a href="#penicillin-allergy" style="color: #0366d6;">Penicillin Allergy Evaluation</a></p>
  </div>
</section>

<!-- REFERENCES -->
<section id="references">
  <h2>References</h2>
  <ul>
    <li><a href="https://www.idsociety.org/practice-guideline/" target="_blank" rel="noopener noreferrer">IDSA Practice Guidelines</a></li>
    <li><a href="https://www.cdc.gov/antibiotic-use/index.html" target="_blank" rel="noopener noreferrer">CDC ‚Äî Antibiotic Use & Stewardship</a></li>
    <li><a href="https://www.who.int/" target="_blank" rel="noopener noreferrer">WHO</a></li>
    <li>Harrison's Principles of Internal Medicine</li>
    <li>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases</li>
  </ul>
</section>

</main>

<script>
/* Sidebar link click - let browser handle anchor navigation natively */
document.querySelectorAll('nav a[href^="#"]').forEach(a=>{
  a.addEventListener('click', e=>{
    // Don't preventDefault - let browser do native anchor navigation
    // scroll-behavior: smooth in CSS handles smooth scrolling
  });
});

/* Collapsible panels: initialization */
function initCollapsibles(){
  document.querySelectorAll('.collapsible').forEach(btn=>{
    // remove previous listener if any to avoid duplicates
    if(btn._listener) btn.removeEventListener('click', btn._listener);
    const listener = function(){
      btn.classList.toggle('active');
      const panel = btn.nextElementSibling;
      if(!panel) return;
      if(panel.style.display === 'block'){
        panel.style.display = 'none';
      } else {
        panel.style.display = 'block';
      }
    };
    btn.addEventListener('click', listener);
    btn._listener = listener;
  });
}
document.addEventListener('DOMContentLoaded', initCollapsibles);

/* Global search/filter that shows matching sections and panels */
function filterAll(query){
  const q = (query||'').trim().toLowerCase();
  // Sections
  document.querySelectorAll('main section').forEach(sec=>{
    const text = sec.innerText.toLowerCase();
    if(!q || text.includes(q)) {
      sec.style.display = '';
    } else {
      sec.style.display = 'none';
    }
  });
  // Buttons & panels
  document.querySelectorAll('.collapsible').forEach(btn=>{
    const panel = btn.nextElementSibling;
    const combined = (btn.innerText + ' ' + (panel?panel.innerText:'' )).toLowerCase();
    if(!q || combined.includes(q)){
      btn.style.display = '';
      if(q && panel && panel.innerText.toLowerCase().includes(q)){
        panel.style.display = 'block';
        btn.classList.add('active');
      }
    } else {
      btn.style.display = 'none';
      if(panel){ panel.style.display = 'none'; btn.classList.remove('active'); }
    }
  });
}

/* Hook global and sidebar search inputs */
const globalSearch = document.getElementById('globalSearch');
const sidebarSearch = document.getElementById('sidebarSearch');
if(globalSearch){
  globalSearch.addEventListener('input', e=>{
    const q = e.target.value;
    if(sidebarSearch) sidebarSearch.value = q;
    filterAll(q);
  });
}
if(sidebarSearch){
  sidebarSearch.addEventListener('input', e=>{
    const q = e.target.value;
    if(globalSearch) globalSearch.value = q;
    filterAll(q);
  });
}

/* Backwards compatibility small helper */
function filterContent(){
  const input = document.getElementById('searchInput');
  if(input) filterAll(input.value);
}

/* Cockcroft-Gault CrCl */
function calcCrCl(){
  const wt = parseFloat(document.getElementById('wt').value);
  const age = parseFloat(document.getElementById('age').value);
  const cr = parseFloat(document.getElementById('cr').value);
  const female = document.getElementById('female').checked;
  const out = document.getElementById('crclResult');
  if(!wt || !age || !cr) { out.innerText = 'Enter weight, age, and serum creatinine.'; return; }
  let crcl = ((140 - age) * wt) / (72 * cr);
  if(female) crcl *= 0.85;
  out.innerText = `Estimated CrCl (Cockcroft-Gault): ${crcl.toFixed(1)} mL/min`;
}

/* SIRS / qSOFA quick */
function calcSIRS_qSOFA(){
  const temp = parseFloat(document.getElementById('temp').value);
  const hr = parseFloat(document.getElementById('hr').value);
  const rr = parseFloat(document.getElementById('rr').value);
  const map = parseFloat(document.getElementById('map').value);
  const mental = document.getElementById('mental').value;
  let sirs = 0;
  if(!isNaN(temp) && (temp < 36 || temp > 38)) sirs++;
  if(!isNaN(hr) && hr > 90) sirs++;
  if(!isNaN(rr) && rr > 20) sirs++;
  let qsofa = 0;
  if(!isNaN(rr) && rr >= 22) qsofa++;
  if(!isNaN(map) && map <= 65) qsofa++;
  if(mental !== 'alert') qsofa++;
  const out = document.getElementById('sirsResult');
  out.innerHTML = `SIRS (partial) criteria met: ${sirs} ${sirs>=2?'<strong>(‚â•2 suggests SIRS)</strong>':''}<br>qSOFA score: ${qsofa} ${qsofa>=2?'<strong>(‚â•2 high risk)</strong>':''}`;
}

/* Initialize open state if page has hash */
(function openHash(){
  if(location.hash){
    const id = location.hash.slice(1);
    const el = document.getElementById(id);
    if(el) el.scrollIntoView({behavior:'smooth', block:'start'});
  }
})();

/* Re-init collapsibles if main content changes */
new MutationObserver(()=> initCollapsibles()).observe(document.getElementById('main'), {childList:true, subtree:true});
</script>

</body>
</html>
